This invention relates to a composition which can be applied to viable tissues such as chronic wounds (e.g. leg ulcers, pressure ulcers, diabetic foot ulcers), acute wounds (e.g. cuts, abrasions, burns), skin and bone for the detection of microbial biofilms as an early warning indicator for tissue at risk of infection. More particularly the invention relates to a composition capable of making biofilms on viable tissues observable while at the same time avoiding wound and skin irritation and retardation of healing. A further embodiment of the invention relates to a kit for use in the detection of biofilms on viable tissues.
Viable tissues are often colonised by a variety of microorganisms, some of which may cause infection. It is becoming increasingly accepted that chronic and acute wound healing is impaired by the presence of microorganisms colonising the wound. Compelling evidence is emerging that these microorganisms may exist in wounds primarily in the form of biofilms. During colonisation, bacteria and other microorganisms such as yeasts and fungi, attach firmly to tissue and form biofilm via the secretion of an extracellular matrix of polymeric substances. This mode of growth imparts a degree of protection to microorganisms within the biofilm in the form of physical protection from topical and systemic antimicrobial agents due to the surrounding matrix. It is also thought that microorganisms within biofilms have altered phenotypes and genotypes compared to their free-swimming, planktonic counterparts. Biofilm microorganisms are known to be metabolically less active, and as such this may also provide a degree of resistance to traditional antimicrobial approaches such as antibiotics, which are known to work against metabolically-active bacteria. Furthermore, the presence of biofilms in wounds also impedes the host immune system in the inflammatory microbial clearance, and the granulation and re-epithelialisation phases, of the normal wound healing process.
Consequently, there is a need to develop methods or devices to rapidly detect the presence of biofilm in viable tissues before and after selected treatment protocols. This would help researchers to understand if microorganisms live in the biofilm state on skin and in wounds, and to allow them to follow maturation or clearance of such biofilm communities. A biofilm detection method or device would also allow researchers to develop effective anti-biofilm strategies and effective wound healing protocols of care, and in clinical practice, it would guide selection of appropriate wound dressings and aid the monitoring of the effectiveness of a treatment protocol given by the wound care practitioner.
Biofilms are typically comprised of bacteria encased within an exopolymeric substance (or matrix) that consists of long-chain polysaccharides with complex linkages such as 1,3- or 1,4-β-linked hexose linkages (examples of some common biofilm polysaccharides are teichoic acid, ketal-linked pryruvates N-acetylglucosamine, and the uronic acids: D-guluronic, D-galacturonic and mannuronic acids), protein (of which some may play a structural role), DNA (extracellular, some of which may have a structural role), lipids, metal ions (Ca2+, Mg2+, Fe3+, etc.) and water. Biofilms may also be associated with devitalised host tissues such as slough and necrotic tissue.
Biofilm extracellular polymeric substances (EPS) are also referred to as biofilm extracellular matrix or bacterial-derived tissue. Whilst biofilm is mainly water by weight and bacteria may only comprise 10-20% of the volume of biofilm, EPS constitutes the majority of the biomass/dry weight of biofilm.
Biofilms such as those found on teeth in the form of dental plaque, are often easy to visualise with the naked eye due to their thickness, colour and the nature of the substrate on which they form. Biofilm visualisation in, for example, a chronic or acute wound is not straightforward due to the colours present in the wound and the contents of the wound. Chronic and acute wounds are usually complex in terms of containing dead or devitalised tissue (slough), exudate, pus, blood, medicaments, dressing components, in addition to bacteria and biofilm. As such it may be difficult to detect the presence of a biofilm in a wound as the visualisation of wound biofilms by the naked eye is difficult. There is thus a need for a means to aid detection of the biofilm for instance by a composition which is able to preferentially stain wound biofilms so that they can be visualised. Once visualised, the biofilm can be treated appropriately.
Surprisingly we have found that it is possible to preferentially stain biofilms by the use of a composition comprising a stain which allows the detection of biofilm.
Accordingly a first aspect of the invention provides a staining composition for use in making biofilm on viable tissue detectable wherein the composition preferentially stains the biofilm and comprises a coloured or fluorescent staining agent in solution in a quantity effective to stain said biofilm and render it detectable.
Preferably the biofilm is made detectable by the naked eye or in conjunction with illumination and/or optical devices.
Preferably the staining agent is a dye which will selectively bind to EPS/bacteria and not to host viable tissue. The staining agent should not significantly stain non-biofilm components in, for example, a chronic or acute wound, such as wound tissue, surrounding skin, slough (dead or devitalized tissue), exudate, blood, pus, inflammatory cells (neutrophils, macrophages), cells involved in the healing process (fibroblasts, endothelial cells, keratinocytes), or medicaments or dressing components that may remain in the wound. Such a staining agent would preferably be a molecule of the required size and structure; for example, a low molecular weight, compact, planar molecule that is capable of diffusion through EPS and bacterial cell membranes. The staining agent may have anionic groups to give colour and possibly fluorescent properties; and may have cationic groups for charge interactions with negatively-charged biofilm EPS polysaccharides and bacterial cell walls. These charged groups should preferably be permanent charges so that they are not affected by the pH of applied formulations or the viable tissue/biofilm environment.
Such a staining agent is preferably of a suitable colour or brightness that it may be possible to observe the stained biofilm directly with the naked eye. However, due to the complex and highly pigmented nature of wounds some colours of stain might be difficult to observe. For example, in necrotic wounds, sloughy wounds, or bleeding wounds there may be hues of black, brown, red, yellow, etc. Whilst blue or green dyes may be considered preferable here, they may appear dark or black if located adjacent to or on brown, red or yellow-coloured tissue. Rather than relying solely on the observer being able to detect the stain with the naked eye, it is preferable to use a stain that can fluoresce so that it is more readily detectable. Many classes of compounds that are potential staining agents are also fluorescent, in that they are capable of absorbing photons of light of certain wavelengths and becoming electronically excited, emitting this light energy in the form of fluorescence. It is possible to detect such fluorescence using light filters that are tailored to the fluorescence emission spectra of relevant molecules so that the observer only views a narrow spectral band that corresponds to the wavelengths of fluorescence. For example, lenses with specific optical filters, such as those used in laser safety, could be used in conjunction with an appropriately-specific light source to detect fluorescence, thereby allowing detection of biofilm on viable tissues. This method of biofilm detection may have advantages over detection using the naked eye in that fluorescent detection is possible even for very thin biofilms, which may be only a few layers of microbial cells thick and does not rely solely on the stain itself being visible.
By preferentially staining it is meant that the staining agent selectively binds to the biofilm rather than the host viable tissue. In this way, the staining agent can be used simply to detect the biofilm by revealing the presence and location the biofilm. The staining agent becomes bound or adsorbed to extracellular biofilm matrix molecules as well as being bound or adsorbed to and/or taken up by the biofilm bacteria cells rather than the tissue of the wound. Preferably the staining of the biofilm by the staining agent reveals the presence of biofilm by making it detectable to the naked eye. For some staining agents the stained biofilm can be made to fluoresce, for instance by illumination with a light source. The fluorescence can make the stained biofilm more visible. The light source is selected to emit light of an appropriate wavelength such that the staining agent absorbs light energy in the form of photons to excite the staining agent and cause it to fluoresce. The observation of fluorescence may be enhanced using appropriate optical filters which exclude non-fluorescent wavelengths for the staining agent, for instance in the form of optically-filtered lenses.
The compositions according to a first aspect of the invention comprise one or more staining agents capable of preferentially staining biofilms. Preferably the staining agent is a dye, the biofilm-staining dye absorbing maximally in the visible region, more preferably 380 nm to 720 nm and even more preferably 500 nm to 600 nm, as this makes a wide range of light sources suitable for use with the composition of the invention or for inclusion in the kit of the invention.
Preferably the staining agent produces sufficient fluorescence for detection, such that a wavelength range suitable for excitation and a distinct and higher wavelength range suitable for fluorescence emission detection can be delivered from illumination devices and detected using optically-filtered lens devices.
Staining agents suitable for use in compositions of the invention are most preferably selected from those based upon organic chemical compounds, more likely to be those containing aromatic ring structures, for example benzene, or extended conjugation, for example in porphyrin or pheophorbides, more likely those with fused polycyclic hydrocarbons, for example naphthalene, anthracene, phenanthraline and pyrene, and most likely those also containing heterocyclic aromatic structures where the heterocyclic atom or atoms are oxygen, nitrogen or sulphur, or a mixture thereof, for example furan, thiophene, pyrrole, pyran, pyridine and oxazine.
These staining agents may also display the properties of fluorescence. Most appropriate are those that absorb and emit light of wavelengths in the visible electromagnetic spectrum (380 nm-720 nm). Such agents are likely to have chemical structures that contain an extended region of conjugation, for example fluorone and its derivatives (alternatively known as xanthenes and rhodamines) such as eosin, erythrosine, Rose Bengal, fluorescein-5-isothiocyanate, 5-chloromethyl fluorescein, 6-carboxy fluorescein, 2,7-Bis-(carboxy ethyl)-5(6)-carboxy fluorescein; Rhodamine B, Rhodamine 6 G, Rhodamine 123, Rhodamine iodoacetamide, Sulphorhodamine B, Sulphorhodamine 101, tetramethyl rhodamines or Texas Red. Derivatives of cyanine such as 3,3′-dihexadecylindocarbocyanines, 3,3′-dipropyloxadicrbocyanine, aluminium phthalocyanine disulphonate, aluminium tetrasulphophthalocyanine, aluminium phthalocyanines, zinc phthalocyanines, napthalocyanines, or the mucopolysaccharide stain Alcian Blue. Acridine and its derivatives such as Acriflavine, Aminacrine, 2-aminoacridine or 9-aminoacridine. Finally, appropriate agents may come from the classes of oxazine derivatives such as Nile Blue, Nile Red, Fura Red or Fura-2; quinolone and its derivatives; adenosine derivatives such as 2′3′-O-(2,4,6-trinotro-cyclohexadienylidine)adenosine 5′-triphosphate or 3′-O—(N-methylanthraniloyl)adenosine 5′-triphosphate; triarylmethanes such as Patent Blue V, Crystal Violet, Brilliant Blue or Fast Green; 5 phenothiaziniums such as Methylene Blue or Toluidine Blue O and its derivatives such as 1-methyl methylene blue or 1,9-dimethyl methylene blue; phenanthridine derivatives such as ethidium or hydroethidine; pheophorbide derivatives such as sodium pheophorbide; and porphyrin derivatives such as chlorin e6, benzoporphyrin derivatives, porphines, 10 meso-tetra porphines, hematoporphyrins or protoporphyrins.
The staining agent is preferably included in the composition at a level of from 0.0001% to 1% by weight, more preferably 0.0025% to 0.025% by weight, even more preferably 0.0025% to 0.01% by weight.
The compositions of the present invention may be in a form that lightly adheres to tissues and may be readily rinsed away after a short duration to aid visualisation of the stained biofilm. A viscous fluid, for instance a water- or glycerol-based gel (in the form of a gel applicator, spray or sheet), foaming mousse, cream or ointment would give intimate contact with a wound bed. Alternatively, a thin, soluble, cast film or a lyophilized, dissolving wafer could be used to provide intimate contact with a wound bed. In any such delivery system the formulation preferably should be easily rinsed away from viable tissues using a standard irrigant such as saline, for a few seconds.
In gel form, the composition may also comprise a viscosifier such as a cellulose derivative such hydroxyethyl cellulose (HEC), carboxymethyl cellulose or hydroxypropyl cellulose; gums; sugar/alcohol derivatives such as glycerol, sorbitol, maltitol, mannitol, maltodextrin or polydextrose; natural polymers such as gelatin, pectin, chitosan or alginate; synthetic polymers such as carbopol, polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol, polyacrylate, polymethacrylate, polyethylene glycol or poloxamers. Preferably the composition in gel form may comprise from 1 to 5% by weight of a viscosifier and most preferably HEC.
The composition of the invention may be in gel form and may also comprise a humectant such as propylene glycol (PG), glycerol, polyethylene glycol, polydextrose, sorbitol, triethanlolamine, cyclomethicone, ammonium lactate or glycerol ester. Preferably the composition comprises from 5% to 15% by weight of a humectant and most preferably PG.
Preferably the composition of the invention comprises excipients to optimise binding of the stain to biofilm. For instance, the composition of the invention may also comprise a metal chelating agent such as tetra sodium ethylene diamine tetraacetic acid (EDTA), citric acid, deferasirox, deferiprone, deferoxamine, deferazoxane, ethylene glycol tetraacetic acid, gluonic acid, nitrilotriacetic acid or trisodium citrate at a level of 0.1 to 2.0% by weight, or an agent to assist penetration of the staining agent into the biofilm such as a surfactant for example Tween 80, Span 20, or coamidopropylbetaine (CAPD) and in particular a cationic quaternary ammonium surfactant such as dialkyl dimethyl ammonium chloride, alkyl pyridinium chloride, benzalkonium chloride (BaCl), benzethonium chloride (BeCl), disodium cocamphodiacetate, cetyl morpholinium ethosulphate or an alkyl trimethyl ammonium chloride at a level of 0.1 to 1.0% by weight. The addition of a surfactant may also act as a foaming agent. For example, the surfactants BeCl, Tween 80, Span 20, CAPD, sodium C14-16 olefin sulfonate or Softisan 649 can act as foaming agents to give the formulation characteristics of a foaming mousse.
Preferably the composition of the invention has a pH in the range of from 5 to 7 and most preferably around 5.5.
Preferably the composition of the invention is in the form of a viscous fluid and comprises a viscosifier such as HEC, a humectant such as PG, a metal chelator such as EDTA, a surfactant such as BeCl and water and in particular 2.0% w/v hydroxyethylcellulose, 10.0% w/v propylene glycol, 0.5% EDTA, 0.5% BeCl and approximately 87% v/v sterile, distilled water. Alternatively, the compositions of the present invention could be in the form of a solution applied to the wound from a syringe, sachet, spray bottle, aerosol bottle, non-propellant pump bottle, brush or a gel sheet, film or dissolving wafer.
The formulation could be terminally sterilized by autoclaving or gamma irradiation. Alternatively, the formulation could be a preserved solution containing, for example preservatives such as DMDM hydantoin or parabens such as methyl-, ethyl- or propyl-paraben.
The composition of the present invention will be used primarily on viable tissues which show signs of clinical infection (inflammation, malodour, purulent exudate, hypoxia, etc.), may be at risk of infection, appear to have slough (host-derived tissue) or biofilm (bacteria-derived tissue) present, or are generally recalcitrant. The composition could also be used at dressing change, in order to detect biofilm, and also to monitor the efficacy of the treatment regime and direct future treatment via the reduction in detected biofilm.
A further aspect of the present invention relates to a kit of parts for use in the detection of biofilms on viable tissue, the kit comprising:
Preferably the kit further comprises optical filters to enable the specific detection of fluorescence in the form of spectacles or integrated optical filters.
The light source may be a white light source such as tungsten, halogen or pulsed xenon lamp that is passed through a “short pass” filter. Preferably the light source is a monochromatic or narrow spectrum source that does not require filtering or attenuation such as a light emitting diode with an output that closely correlates with the spectral characteristics of the staining agent. As such the light source is preferably small, portable, hand-held and generates no or negligible heat. The light source may be multiple use or fully disposable.
Preferably the kit further comprises spectacles, or the light source contains an integrated lens, for use in detecting the biofilm wherein the spectacles or lens contain a filter to exclude all wavelengths of light below the absorption maxima (Absmax) of the staining agent. In this way the user is assisted in detecting the fluorescence of the staining agent present in the biofilm. More preferably the spectacles or lens filter is efficient at transmitting wavelengths of light corresponding to the fluorescence emission spectra of the staining agent. The spectacles can be multiple use or fully disposable (in the same way that an integrated lens in the light source could be).
Preferably the kit further comprises a wound irrigation solution for rinsing the viable tissue before and/or after illumination with the light source.
In an example of typical use, a composition according to the invention is applied to the whole wound or desired regions in order to achieve a thin but consistent layer of composition for instance 0.1 to 0.5 cm in thickness. The composition is left in place for 0.1 to 15 minutes, more preferably 0.5 to 2 minutes. Prior to any illumination, the formulation can be left in place or more preferably excess formulation is rinsed away from the wound using a suitable wound irrigation solution. Rinsing the excess formulation away can enable the staining to show where the biofilm is in the wound so that these areas can be treated for example by curette.
The wound is then inspected for presence of preferentially stained biofilm. This may be done with the naked eye or the wound can be illuminated with a light source at a distance in the range of 1 to 50 cm. Preferably the light source is at a distance of 5 to 20 cm. The light source spectral output is selected to correspond to the fluorescence emission spectra of the staining agent; for example, for Rose Bengal, which has a fluorescence maxima of 575 nm, a suitable light source might emit wavelengths of 550-600 nm. This causes the agent in the stained biofilm to fluoresce. Preferably the user wears spectacles to observe the wound or observes the wound through an integrated lens in the light source. The spectacles or lens have a light filtration system which excludes wavelengths of light below the fluorescence emission range of the staining agent and allows any fluorescence to be seen remarkably clearly and specifically and thus, detection of any biofilm present.
Typically, treatment should take place at subsequent dressing changes. The wound can be further inspected for presence and reduction of biofilm with the naked eye or with the light source and spectacles or integrated lens. The wound can then be dressed with an appropriate primary and secondary dressing.
The following examples are illustrative of the present invention.
Assessment of Biofilm Stains using the Constant-Depth Biofilm Fermenter
A constant depth biofilm fermenter (CDFF) was used to culture 4-day mixed biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. Briefly, biofilms were formed in recesses in 15 PTFE pans around the rim of a rotating steel turntable onto which inoculum or sterile growth media was allowed to steadily drip. A scraper bar distributed bacterial inoculum or media over the pans as the turntable rotated, maintaining the biofilms at a steady depth. Each pan contained 5 removable plugs, 4 mm in diameter which were recessed to a depth of 300 μm. The resulting biofilms that grew in the plug recesses were reproducible in terms of appearance and microbiological composition and could be removed from the CDFF through a sampling port using sterile instruments. In duplicate, biofilm-containing pans were removed from the CDFF, rinsed once by dipping in sterile saline for 5 seconds, then incubated in 10 ml volumes of the following potential biofilm stains at 100 μM concentration in deionised water unless stated, in the dark for two minutes: Erythrosine; Rose Bengal; Fast Green; Rose Bengal with 2% w/v EDTA and 1% w/v benzalkonium chloride (BaCl) (RBEB); Rose Bengal with 2% w/v tetra sodium EDTA and 1% w/v benzalkonium chloride in a 2% w/v hydroxyethyl cellulose and 10% w/v propylene glycol gel (Gel-RBEB). Following another rinse in saline, six plugs for each stain were incubated overnight at 37° C. in 6 ml volumes of 2% sodium dodecyl sulphate (SDS) in water for digestion. Samples were then spun at 13,000 rpm for 10 minutes to separate the supernatant from digested cell debris. Absorption spectra of the aspired supernatants were then measured in a spectrophotometer and these spectra compared to spectra of known concentrations (100 μM) of each stain in 2% SDS.
Assessment of Biofilm Stains using the CDC Biofilm Reactor
A Centre for Disease Control (CDC) biofilm reactor was used to culture 48 hour mixed biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. Briefly, biofilms were formed on coupons on reactor rods which were held within the reactor vessel containing a continuously mixed culture of S. aureus and P. aeruginosa at 35° C. Biofilm-containing coupons were removed from the rods, rinsed once by dipping in sterile saline for 5 seconds, then incubated in 10 ml volumes of the following biofilm stains at 100 μM concentration in deionised water, in the dark for two minutes: Erythrosine; Rose Bengal; Alcian Blue; Rhodamine B; Rhodamine 123; Rose Bengal with 2% w/v EDTA and 1% w/v BaCl (RBEB). Following another rinse in saline, nine coupons for each stain were each added to 2 ml volumes of 2% SDS for stomaching at ‘high’ setting for 1 minute then incubated overnight in the dark at 37° C., for digestion. Samples were then spun at 13,000 rpm for 5 minutes to separate the supernatant from digested cell debris. Absorption spectra of the aspired supernatants were then measured in a spectrophotometer and these spectra compared to spectra of known concentrations (100 μM) of each stain in 2% SDS.
Assessment of Biofilm Stains using a Pork Belly Biofilm Model
A pork belly biofilm model was used to further assess biofilm stains. Pieces of pork belly were cut using a 20 mm bore and a 6 mm borer was used to create indentations in the centre of the samples. Samples were then sterilized by gamma irradiation. Samples were inoculated with 10 μl volumes of a ˜1×107 cfu/ml mixed suspension of S. aureus and P. aeruginosa then incubated at 35° C. in Parafilm-sealed Petri dishes for 72-96 hours. Samples that appeared to have visible biofilms in the central bore hole only were then stained by dipping the samples into 10 ml volumes of 100 μM Rose Bengal with 2% w/v EDTA and 1% w/v BaCl (RBEB) for two minutes with rinsing in saline before and after staining. Control samples were not stained and therefore only dipped in saline for 2 minutes. Samples were then photographed, examples of which are shown in
Rose Bengal Staining of Biofilms Crown using a Membrane Filter Biofilm Model
A membrane filter biofilm model was used to study the effect of Rose Bengal concentration on the efficacy of biofilm staining. Briefly, a 5 μl volume of a 5×105 cfu/ml suspension of S. aureus or P. aeruginosa was added to the centre of sterile membrane filter discs (pore size 0.2 μm; Anodisc, Whatman) which were placed onto 7 ml volumes of sterile Tryptic Soya Broth in lidded 6-well plates. Samples were incubated for 4 hours (immature biofilms), and 24 and 48 hours (mature biofilms), and excess planktonic cells were rinsed from the filters. The biofilms on the filters were stained by pipetting 2 ml volumes of Rose Bengal (60 μM or 300 μM) or saline (negative control) for 30 seconds, followed by rinsing. Rose Bengal was recovered from the biofilm samples by stomaching and overnight digestion in 2% sodium dodecyl sulphate, centrifugation, then measuring of absorption spectra in a UV-vis spectrophotometer. Rose Bengal uptake per sample was determined by comparison of absorption values with a standard curve of Rose Bengal in 2% SDS. Tables 1 and 2 show that mature S. aureus and P. aeruginosa biofilms took up Rose Bengal in a dye concentration- and biofilm age-dependent manner. Only at the highest concentrations of 300 μM did the immature, 4-hour biofilms appear to be stained, although this was likely due to some staining of the filters themselves.
Number | Date | Country | Kind |
---|---|---|---|
1020236 | Nov 2010 | GB | national |
This application is a continuation application of Application No. 13/990,755, filed Feb. 19, 2014 which is a U.S. National Phase of International Application No. PCT/GB2011/001665, filed on Nov. 30, 2011, designating the United States of America and published in the English language, which is incorporated herein by reference in their entirety and to which application we claim priority under 35 USC § 120.
Number | Name | Date | Kind |
---|---|---|---|
2396514 | Kreidl et al. | Mar 1946 | A |
2785106 | Mendelsohn | Mar 1957 | A |
3061469 | Manowitz et al. | Oct 1962 | A |
3092552 | Romans | Jun 1963 | A |
4258056 | Lentsch | Mar 1981 | A |
4612337 | Fox, Jr. et al. | Sep 1986 | A |
4655758 | Ring et al. | Apr 1987 | A |
4728323 | Matson | Mar 1988 | A |
4829129 | Kelley | May 1989 | A |
4889654 | Mason et al. | Dec 1989 | A |
4906100 | Rice et al. | Mar 1990 | A |
4973848 | Kolobanov et al. | Nov 1990 | A |
5064652 | Bay | Nov 1991 | A |
5326567 | Capelli | Jul 1994 | A |
5340924 | Tomita et al. | Aug 1994 | A |
5407656 | Roozdar | Apr 1995 | A |
5527534 | Myhling | Jun 1996 | A |
5567495 | Modak et al. | Oct 1996 | A |
5616347 | Alliger et al. | Apr 1997 | A |
5662913 | Capelli | Sep 1997 | A |
5670169 | Cornell | Sep 1997 | A |
5709870 | Yoshimura et al. | Jan 1998 | A |
5731083 | Bahia et al. | Mar 1998 | A |
5744151 | Capelli | Apr 1998 | A |
5744155 | Friedman et al. | Apr 1998 | A |
5762620 | Cartmell et al. | Jun 1998 | A |
5820918 | Ronan et al. | Oct 1998 | A |
5848995 | Walder | Dec 1998 | A |
5860947 | Stamler | Jan 1999 | A |
5998488 | Shinohara et al. | Dec 1999 | A |
6075177 | Bahia et al. | Jun 2000 | A |
6207601 | Maurer et al. | Mar 2001 | B1 |
6290496 | Azar et al. | Sep 2001 | B1 |
6413556 | Bathurst et al. | Jul 2002 | B1 |
6468965 | Cutler | Oct 2002 | B1 |
6548730 | Patel et al. | Apr 2003 | B1 |
6555508 | Paul et al. | Apr 2003 | B1 |
6605751 | Gibbins et al. | Aug 2003 | B1 |
6669981 | Parsons et al. | Dec 2003 | B2 |
6750262 | Haehnle et al. | Jun 2004 | B1 |
6753063 | Pung et al. | Jun 2004 | B1 |
7033511 | Zawada et al. | Apr 2006 | B2 |
7267828 | Parsons et al. | Sep 2007 | B2 |
8637072 | Kershaw et al. | Jan 2014 | B2 |
9149035 | Percival et al. | Oct 2015 | B2 |
9545390 | Percival et al. | Jan 2017 | B2 |
10016537 | Menon et al. | Jul 2018 | B2 |
10046096 | Askem et al. | Aug 2018 | B2 |
10076447 | Barta et al. | Sep 2018 | B2 |
10076587 | Locke et al. | Sep 2018 | B2 |
10143784 | Walton et al. | Dec 2018 | B2 |
10426670 | von Blucher et al. | Oct 2019 | B2 |
10426747 | Johnson | Oct 2019 | B2 |
10426874 | Chien et al. | Oct 2019 | B2 |
10426875 | Blott et al. | Oct 2019 | B2 |
10426938 | Locke et al. | Oct 2019 | B2 |
10434015 | Taylor et al. | Oct 2019 | B2 |
10434142 | Niazi et al. | Oct 2019 | B2 |
10434210 | Olson et al. | Oct 2019 | B2 |
10434284 | Hanson et al. | Oct 2019 | B2 |
10449094 | Donda et al. | Oct 2019 | B2 |
D866756 | Allen et al. | Nov 2019 | S |
10463760 | Karthikeyan et al. | Nov 2019 | B2 |
10463773 | Haggstrom et al. | Nov 2019 | B2 |
10470933 | Riesinger | Nov 2019 | B2 |
10470936 | Wohlgemuth et al. | Nov 2019 | B2 |
10471122 | Shi et al. | Nov 2019 | B2 |
10471190 | Locke et al. | Nov 2019 | B2 |
10478345 | Barta et al. | Nov 2019 | B2 |
10478346 | Knutson | Nov 2019 | B2 |
10478394 | Yu | Nov 2019 | B2 |
10485707 | Sexton | Nov 2019 | B2 |
10485891 | Andrews et al. | Nov 2019 | B2 |
10485892 | Hands et al. | Nov 2019 | B2 |
10485906 | Freedman et al. | Nov 2019 | B2 |
10486135 | Yang et al. | Nov 2019 | B2 |
10492956 | Zamierowski | Dec 2019 | B2 |
10493178 | Marchant et al. | Dec 2019 | B2 |
10493184 | Collinson et al. | Dec 2019 | B2 |
10493185 | Stokes et al. | Dec 2019 | B2 |
10500099 | Hung et al. | Dec 2019 | B2 |
10500103 | Croizat et al. | Dec 2019 | B2 |
10500104 | Sookraj | Dec 2019 | B2 |
10500173 | Yang et al. | Dec 2019 | B2 |
10500235 | Wardell | Dec 2019 | B2 |
10500300 | Dybe et al. | Dec 2019 | B2 |
10500301 | Laurensou | Dec 2019 | B2 |
10500302 | Holm et al. | Dec 2019 | B2 |
10501487 | Andrews et al. | Dec 2019 | B2 |
10506928 | Locke et al. | Dec 2019 | B2 |
10507141 | Allen et al. | Dec 2019 | B2 |
10507259 | Cree et al. | Dec 2019 | B2 |
10512707 | Whalen, III et al. | Dec 2019 | B2 |
10525170 | Havenstrite et al. | Jan 2020 | B2 |
10532137 | Pratt et al. | Jan 2020 | B2 |
10532194 | Locke et al. | Jan 2020 | B2 |
10537657 | Phillips et al. | Jan 2020 | B2 |
10542936 | Goldberg et al. | Jan 2020 | B2 |
10543133 | Shaw et al. | Jan 2020 | B2 |
10543293 | Suschek | Jan 2020 | B2 |
10548777 | Locke et al. | Feb 2020 | B2 |
10549008 | Yoo | Feb 2020 | B2 |
10549016 | Bushko et al. | Feb 2020 | B2 |
10549017 | Hsiao et al. | Feb 2020 | B2 |
10555838 | Wu et al. | Feb 2020 | B2 |
10555839 | Hartwell | Feb 2020 | B2 |
10556044 | Robinson et al. | Feb 2020 | B2 |
10561533 | Hoggarth et al. | Feb 2020 | B2 |
10561536 | Holm et al. | Feb 2020 | B2 |
10568767 | Addison et al. | Feb 2020 | B2 |
10568768 | Long et al. | Feb 2020 | B2 |
10568770 | Robinson et al. | Feb 2020 | B2 |
10568771 | MacDonald et al. | Feb 2020 | B2 |
10568773 | Tuck et al. | Feb 2020 | B2 |
10568983 | Gerdes et al. | Feb 2020 | B2 |
10575991 | Dunn | Mar 2020 | B2 |
10575992 | Sarangapani et al. | Mar 2020 | B2 |
10576037 | Harrell | Mar 2020 | B2 |
10576189 | Locke et al. | Mar 2020 | B2 |
10583042 | Sarangapani et al. | Mar 2020 | B2 |
10583228 | Shuler et al. | Mar 2020 | B2 |
10589007 | Coulthard et al. | Mar 2020 | B2 |
10590184 | Kuo | Mar 2020 | B2 |
10610414 | Hartwell et al. | Apr 2020 | B2 |
10610415 | Griffey et al. | Apr 2020 | B2 |
10610623 | Robinson et al. | Apr 2020 | B2 |
10617569 | Bonn | Apr 2020 | B2 |
10617608 | Shin et al. | Apr 2020 | B2 |
10617769 | Huang | Apr 2020 | B2 |
10617784 | Yu et al. | Apr 2020 | B2 |
10617786 | Kluge et al. | Apr 2020 | B2 |
10618266 | Wright et al. | Apr 2020 | B2 |
10624984 | Courage et al. | Apr 2020 | B2 |
10625002 | Locke et al. | Apr 2020 | B2 |
10632019 | Vitaris | Apr 2020 | B2 |
10632224 | Hardy et al. | Apr 2020 | B2 |
10639206 | Hu et al. | May 2020 | B2 |
10639350 | Arber et al. | May 2020 | B2 |
10639404 | Lichtenstein | May 2020 | B2 |
10646614 | Grinstaff et al. | May 2020 | B2 |
10653562 | Robinson et al. | May 2020 | B2 |
10653782 | Ameer et al. | May 2020 | B2 |
10653810 | Datt et al. | May 2020 | B2 |
10653821 | Nichols | May 2020 | B2 |
10653823 | Bharti et al. | May 2020 | B2 |
10660799 | Wu et al. | May 2020 | B2 |
10660851 | Millis et al. | May 2020 | B2 |
10660992 | Canner et al. | May 2020 | B2 |
10660994 | Askem et al. | May 2020 | B2 |
10667955 | Allen et al. | Jun 2020 | B2 |
10667956 | Van Holten et al. | Jun 2020 | B2 |
10682257 | Lu | Jun 2020 | B2 |
10682258 | Manwaring et al. | Jun 2020 | B2 |
10682259 | Hunt et al. | Jun 2020 | B2 |
10682318 | Twomey et al. | Jun 2020 | B2 |
10682386 | Ellis-Behnke et al. | Jun 2020 | B2 |
10682446 | Askem et al. | Jun 2020 | B2 |
10687983 | Dahlberg et al. | Jun 2020 | B2 |
10687985 | Lee et al. | Jun 2020 | B2 |
10688215 | Munro et al. | Jun 2020 | B2 |
10688217 | Hanson et al. | Jun 2020 | B2 |
RE48117 | Albert et al. | Jul 2020 | E |
10702419 | Locke et al. | Jul 2020 | B2 |
10702420 | Hammond et al. | Jul 2020 | B2 |
10703942 | Tunius | Jul 2020 | B2 |
10709760 | Gronberg et al. | Jul 2020 | B2 |
10709807 | Kshirsagar | Jul 2020 | B2 |
10709883 | Spector | Jul 2020 | B2 |
10716711 | Locke et al. | Jul 2020 | B2 |
10716874 | Koyama et al. | Jul 2020 | B2 |
10729589 | Dorian et al. | Aug 2020 | B2 |
10729590 | Simmons et al. | Aug 2020 | B2 |
10729826 | Lin | Aug 2020 | B2 |
10736787 | Hannigan et al. | Aug 2020 | B2 |
10736788 | Locke et al. | Aug 2020 | B2 |
10736985 | Odermatt et al. | Aug 2020 | B2 |
10737003 | Fujisaki | Aug 2020 | B2 |
10743900 | Ingram et al. | Aug 2020 | B2 |
10744040 | Kazala, Jr. et al. | Aug 2020 | B2 |
10744041 | Hartwell | Aug 2020 | B2 |
10744225 | Lindgren et al. | Aug 2020 | B2 |
10744237 | Guidi et al. | Aug 2020 | B2 |
10744238 | Guidi et al. | Aug 2020 | B2 |
10744239 | Armstrong et al. | Aug 2020 | B2 |
10744240 | Simmons et al. | Aug 2020 | B2 |
10751212 | Raza et al. | Aug 2020 | B2 |
10751442 | Bonnefin et al. | Aug 2020 | B2 |
10751452 | Topaz | Aug 2020 | B2 |
10758423 | Pigg et al. | Sep 2020 | B2 |
10758424 | Blott et al. | Sep 2020 | B2 |
10758425 | Blott et al. | Sep 2020 | B2 |
10758426 | Eddy | Sep 2020 | B2 |
10758651 | Blott et al. | Sep 2020 | B2 |
10765561 | Lattimore et al. | Sep 2020 | B2 |
10765783 | Locke et al. | Sep 2020 | B2 |
10772767 | Bjork et al. | Sep 2020 | B2 |
10772999 | Svensby | Sep 2020 | B2 |
10779993 | Bishop et al. | Sep 2020 | B2 |
10780114 | Udagawa et al. | Sep 2020 | B2 |
10780194 | Flach et al. | Sep 2020 | B2 |
10780201 | Lin | Sep 2020 | B2 |
10780202 | Askem et al. | Sep 2020 | B2 |
10780203 | Coulthard et al. | Sep 2020 | B2 |
10782238 | Hicks et al. | Sep 2020 | B2 |
10792191 | Robinson et al. | Oct 2020 | B2 |
10792192 | Tout et al. | Oct 2020 | B2 |
10792337 | Leung et al. | Oct 2020 | B2 |
10792404 | Hu et al. | Oct 2020 | B2 |
10792482 | Randolph et al. | Oct 2020 | B2 |
10800905 | Delli-Santi et al. | Oct 2020 | B2 |
10806819 | Shuler | Oct 2020 | B2 |
20020091074 | Wooley et al. | Jul 2002 | A1 |
20020160941 | Kruzel | Oct 2002 | A1 |
20020172709 | Nielsen et al. | Nov 2002 | A1 |
20020183808 | Biel | Dec 2002 | A1 |
20030180345 | Hill et al. | Sep 2003 | A1 |
20030180346 | Woods | Sep 2003 | A1 |
20040001880 | Bowler et al. | Jan 2004 | A1 |
20040247652 | Sabesan | Dec 2004 | A1 |
20050059731 | Albrecht et al. | Mar 2005 | A1 |
20060019571 | Lange et al. | Jan 2006 | A1 |
20060051385 | Scholz | Mar 2006 | A1 |
20060051430 | Arata et al. | Mar 2006 | A1 |
20060115440 | Arata et al. | Jun 2006 | A1 |
20060155260 | Blott et al. | Jul 2006 | A1 |
20060172000 | Cullen et al. | Aug 2006 | A1 |
20060234959 | Biel et al. | Oct 2006 | A1 |
20060254988 | Frampton | Nov 2006 | A1 |
20070042024 | Gladman et al. | Feb 2007 | A1 |
20070134136 | Polyakov et al. | Jun 2007 | A1 |
20070166399 | Burton et al. | Jul 2007 | A1 |
20070185426 | Ambrosio et al. | Aug 2007 | A1 |
20070219512 | Heaton et al. | Sep 2007 | A1 |
20070239078 | Jaeb | Oct 2007 | A1 |
20070255192 | Patel et al. | Nov 2007 | A1 |
20080112920 | Chia et al. | May 2008 | A1 |
20080188558 | Godal et al. | Aug 2008 | A1 |
20080226724 | Ji et al. | Sep 2008 | A1 |
20090012440 | Bray et al. | Jan 2009 | A1 |
20090177135 | Rogers et al. | Jul 2009 | A1 |
20090234307 | Vitaris | Sep 2009 | A1 |
20090259203 | Hu et al. | Oct 2009 | A1 |
20090293887 | Wilkes et al. | Dec 2009 | A1 |
20090299303 | Seegert | Dec 2009 | A1 |
20100015208 | Kershaw et al. | Jan 2010 | A1 |
20100030178 | MacMeccan et al. | Feb 2010 | A1 |
20100113537 | Nonaka | May 2010 | A1 |
20100125233 | Edward S. et al. | May 2010 | A1 |
20100125258 | Coulthard et al. | May 2010 | A1 |
20100129633 | Law | May 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100185163 | Heagle | Jul 2010 | A1 |
20100298790 | Guidi et al. | Nov 2010 | A1 |
20100310845 | Bond et al. | Dec 2010 | A1 |
20110015595 | Robinson et al. | Jan 2011 | A1 |
20110028918 | Hartwell | Feb 2011 | A1 |
20110112457 | Holm et al. | May 2011 | A1 |
20110117025 | Dacosta et al. | May 2011 | A1 |
20110178451 | Robinson et al. | Jul 2011 | A1 |
20110224593 | Tunius | Sep 2011 | A1 |
20110224630 | Simmons et al. | Sep 2011 | A1 |
20110230849 | Coulthard et al. | Sep 2011 | A1 |
20110237994 | Russ et al. | Sep 2011 | A1 |
20110251566 | Zimnitsky et al. | Oct 2011 | A1 |
20110257572 | Locke et al. | Oct 2011 | A1 |
20110257573 | Hong et al. | Oct 2011 | A1 |
20110275972 | Rosenberg | Nov 2011 | A1 |
20110319808 | Bowler et al. | Dec 2011 | A1 |
20120071845 | Hu et al. | Mar 2012 | A1 |
20120130332 | Cotton et al. | May 2012 | A1 |
20120136325 | Allen et al. | May 2012 | A1 |
20120202398 | Marshall et al. | Aug 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20130053795 | Coulthard et al. | Feb 2013 | A1 |
20130123728 | Pratt et al. | May 2013 | A1 |
20130226063 | Taylor et al. | Aug 2013 | A1 |
20140005618 | Locke et al. | Jan 2014 | A1 |
20140074053 | Locke et al. | Mar 2014 | A1 |
20140161728 | Bowler et al. | Jun 2014 | A1 |
20140188060 | Robinson et al. | Jul 2014 | A1 |
20140194838 | Wibaux et al. | Jul 2014 | A1 |
20140200532 | Robinson et al. | Jul 2014 | A1 |
20140236112 | Von Wolff et al. | Aug 2014 | A1 |
20140256925 | Catchmark et al. | Sep 2014 | A1 |
20140276499 | Locke et al. | Sep 2014 | A1 |
20140296804 | Hicks et al. | Oct 2014 | A1 |
20140308338 | Nierle et al. | Oct 2014 | A1 |
20140309574 | Cotton | Oct 2014 | A1 |
20150018433 | Leipzig et al. | Jan 2015 | A1 |
20150057624 | Simmons et al. | Feb 2015 | A1 |
20150071985 | Walker et al. | Mar 2015 | A1 |
20150079152 | Wuollett et al. | Mar 2015 | A1 |
20150094674 | Pratt et al. | Apr 2015 | A1 |
20150104486 | Bonnefin et al. | Apr 2015 | A1 |
20150112311 | Hammond et al. | Apr 2015 | A1 |
20150119831 | Robinson et al. | Apr 2015 | A1 |
20150119834 | Locke et al. | Apr 2015 | A1 |
20150141941 | Allen et al. | May 2015 | A1 |
20150148785 | Kleiner | May 2015 | A1 |
20150174304 | Askem et al. | Jun 2015 | A1 |
20150245949 | Locke et al. | Sep 2015 | A1 |
20150246164 | Heaton et al. | Sep 2015 | A1 |
20150250979 | Loske | Sep 2015 | A1 |
20150265741 | Duncan et al. | Sep 2015 | A1 |
20150265743 | Hanson et al. | Sep 2015 | A1 |
20150320901 | Chandrashekhar-Bhat et al. | Nov 2015 | A1 |
20160008293 | Shi et al. | Jan 2016 | A1 |
20160038626 | Locke et al. | Feb 2016 | A1 |
20160051724 | Sahin et al. | Feb 2016 | A1 |
20160067107 | Cotton | Mar 2016 | A1 |
20160100987 | Hartwell et al. | Apr 2016 | A1 |
20160101207 | Parsons et al. | Apr 2016 | A1 |
20160106878 | Yang et al. | Apr 2016 | A1 |
20160106892 | Hartwell | Apr 2016 | A1 |
20160166422 | Karim et al. | Jun 2016 | A1 |
20160193244 | Ota et al. | Jul 2016 | A1 |
20160222548 | Agboh | Aug 2016 | A1 |
20160271178 | Hauser et al. | Sep 2016 | A1 |
20160287743 | Andrews | Oct 2016 | A1 |
20160339158 | Collinson et al. | Nov 2016 | A1 |
20160374847 | Lachenbruch et al. | Dec 2016 | A1 |
20170014275 | Schneider | Jan 2017 | A1 |
20170049111 | Patton et al. | Feb 2017 | A1 |
20170072669 | Sekido et al. | Mar 2017 | A1 |
20170079276 | Percival et al. | Mar 2017 | A1 |
20170128269 | Coulthard et al. | May 2017 | A1 |
20170189237 | Locke et al. | Jul 2017 | A1 |
20170189575 | Lee et al. | Jul 2017 | A1 |
20170209615 | Tornero Garcia et al. | Jul 2017 | A1 |
20170232161 | Fewkes et al. | Aug 2017 | A1 |
20170258956 | Flach et al. | Sep 2017 | A1 |
20170347661 | Parsons | Dec 2017 | A1 |
20170367895 | Holm et al. | Dec 2017 | A1 |
20170368239 | Askem et al. | Dec 2017 | A1 |
20180008742 | Hoggarth et al. | Jan 2018 | A1 |
20180014974 | Hoggarth et al. | Jan 2018 | A1 |
20180023217 | Patton et al. | Jan 2018 | A1 |
20180030321 | Tunius | Feb 2018 | A1 |
20180042789 | Bradford et al. | Feb 2018 | A1 |
20180078423 | Magin et al. | Mar 2018 | A1 |
20180086903 | Zhang et al. | Mar 2018 | A1 |
20180118809 | Mearns Spragg | May 2018 | A1 |
20180133066 | Ahsani et al. | May 2018 | A1 |
20180140467 | Hunt | May 2018 | A1 |
20180140822 | Robinson et al. | May 2018 | A1 |
20180200414 | Askem et al. | Jul 2018 | A1 |
20180221531 | Bender et al. | Aug 2018 | A1 |
20180236124 | Young et al. | Aug 2018 | A1 |
20180243463 | Chatterjee et al. | Aug 2018 | A1 |
20180243464 | Hwang et al. | Aug 2018 | A1 |
20180244857 | Lee et al. | Aug 2018 | A1 |
20180272052 | Locke et al. | Sep 2018 | A1 |
20180296397 | Askem et al. | Oct 2018 | A1 |
20180303873 | Been et al. | Oct 2018 | A1 |
20180311419 | Locke et al. | Nov 2018 | A1 |
20180333522 | Pratt et al. | Nov 2018 | A1 |
20180344533 | Rovaniemi | Dec 2018 | A1 |
20180353334 | Locke et al. | Dec 2018 | A1 |
20180353337 | Locke | Dec 2018 | A1 |
20180353339 | Locke et al. | Dec 2018 | A1 |
20180353340 | Robinson et al. | Dec 2018 | A1 |
20180353344 | Locke et al. | Dec 2018 | A1 |
20180353662 | Locke et al. | Dec 2018 | A1 |
20180353663 | Locke et al. | Dec 2018 | A1 |
20180360667 | Droche | Dec 2018 | A1 |
20190000677 | Munro | Jan 2019 | A1 |
20190015258 | Gowans et al. | Jan 2019 | A1 |
20190015468 | Yadav et al. | Jan 2019 | A1 |
20190030223 | Lin | Jan 2019 | A1 |
20190046682 | Choi et al. | Feb 2019 | A1 |
20190060127 | Locke et al. | Feb 2019 | A1 |
20190083752 | Howell et al. | Mar 2019 | A1 |
20190117465 | Osborne et al. | Apr 2019 | A1 |
20190117466 | Kazala, Jr. et al. | Apr 2019 | A1 |
20190117861 | Locke et al. | Apr 2019 | A1 |
20190125590 | Rehbein et al. | May 2019 | A1 |
20190133830 | Bishop et al. | May 2019 | A1 |
20190151155 | Bonn | May 2019 | A1 |
20190151159 | Gowans et al. | May 2019 | A1 |
20190151495 | Helary et al. | May 2019 | A1 |
20190184052 | Ilan et al. | Jun 2019 | A1 |
20190216953 | Bowler et al. | Jul 2019 | A1 |
20190231600 | Locke et al. | Aug 2019 | A1 |
20190231602 | Locke et al. | Aug 2019 | A1 |
20190231943 | Robinson et al. | Aug 2019 | A1 |
20190274889 | Steward et al. | Sep 2019 | A1 |
20190282728 | Kellar et al. | Sep 2019 | A1 |
20190290799 | Arshi et al. | Sep 2019 | A1 |
20190298249 | Bates et al. | Oct 2019 | A1 |
20190298577 | Locke et al. | Oct 2019 | A1 |
20190298578 | Shulman et al. | Oct 2019 | A1 |
20190298579 | Moore et al. | Oct 2019 | A1 |
20190298580 | Hall et al. | Oct 2019 | A1 |
20190298582 | Addison et al. | Oct 2019 | A1 |
20190298881 | Ramjit et al. | Oct 2019 | A1 |
20190298882 | Nelson | Oct 2019 | A1 |
20190298895 | Selby et al. | Oct 2019 | A1 |
20190307611 | Askem et al. | Oct 2019 | A1 |
20190307612 | Hartwell et al. | Oct 2019 | A1 |
20190307934 | Allen et al. | Oct 2019 | A1 |
20190307935 | Simmons et al. | Oct 2019 | A1 |
20190314187 | Emslander et al. | Oct 2019 | A1 |
20190314209 | Ha et al. | Oct 2019 | A1 |
20190314544 | Filho et al. | Oct 2019 | A1 |
20190321232 | Jardret et al. | Oct 2019 | A1 |
20190321509 | Chakravarthy et al. | Oct 2019 | A1 |
20190321526 | Robinson et al. | Oct 2019 | A1 |
20190322795 | Kubo et al. | Oct 2019 | A1 |
20190328580 | Emslander et al. | Oct 2019 | A1 |
20190336343 | Etchells et al. | Nov 2019 | A1 |
20190336344 | Locke | Nov 2019 | A1 |
20190336345 | Bannwart | Nov 2019 | A1 |
20190336346 | Locke et al. | Nov 2019 | A1 |
20190336640 | Vismara et al. | Nov 2019 | A1 |
20190336641 | Nisbet | Nov 2019 | A1 |
20190336643 | Luukko et al. | Nov 2019 | A1 |
20190336658 | Heaton et al. | Nov 2019 | A1 |
20190336739 | Locke et al. | Nov 2019 | A1 |
20190343687 | Locke et al. | Nov 2019 | A1 |
20190343889 | Luukko et al. | Nov 2019 | A1 |
20190343979 | Kearney et al. | Nov 2019 | A1 |
20190343993 | Weston | Nov 2019 | A1 |
20190343994 | Greener | Nov 2019 | A1 |
20190344242 | Kim et al. | Nov 2019 | A1 |
20190350763 | Pratt et al. | Nov 2019 | A1 |
20190350764 | Zochowski et al. | Nov 2019 | A1 |
20190350765 | Heagle et al. | Nov 2019 | A1 |
20190350775 | Biasutti et al. | Nov 2019 | A1 |
20190350970 | Saphier et al. | Nov 2019 | A1 |
20190351092 | Silver et al. | Nov 2019 | A1 |
20190351093 | Stein et al. | Nov 2019 | A1 |
20190351094 | Maher et al. | Nov 2019 | A1 |
20190351095 | Maher et al. | Nov 2019 | A1 |
20190351111 | Locke et al. | Nov 2019 | A1 |
20190358088 | Lavocah et al. | Nov 2019 | A1 |
20190358361 | McInnes et al. | Nov 2019 | A1 |
20190358372 | Askem et al. | Nov 2019 | A1 |
20190365948 | Deegan et al. | Dec 2019 | A1 |
20190365962 | Lee et al. | Dec 2019 | A1 |
20190374408 | Robles et al. | Dec 2019 | A1 |
20190374673 | Hoefinghoff et al. | Dec 2019 | A1 |
20190380878 | Edwards et al. | Dec 2019 | A1 |
20190380881 | Albert et al. | Dec 2019 | A1 |
20190380882 | Taylor et al. | Dec 2019 | A1 |
20190380883 | MacPhee et al. | Dec 2019 | A1 |
20190381222 | Locke et al. | Dec 2019 | A9 |
20190388577 | Chandrashekhar-Bhat et al. | Dec 2019 | A1 |
20190388579 | MacPhee et al. | Dec 2019 | A1 |
20190388589 | MacPhee et al. | Dec 2019 | A1 |
20200000640 | Mondal et al. | Jan 2020 | A1 |
20200000642 | Waite | Jan 2020 | A1 |
20200000643 | Locke | Jan 2020 | A1 |
20200000955 | Andrews et al. | Jan 2020 | A1 |
20200000956 | Huang et al. | Jan 2020 | A1 |
20200000960 | Kellar et al. | Jan 2020 | A1 |
20200000985 | Seddon et al. | Jan 2020 | A1 |
20200008981 | Wheldrake | Jan 2020 | A1 |
20200009289 | Torabinejad et al. | Jan 2020 | A1 |
20200009400 | Ribeiro et al. | Jan 2020 | A1 |
20200017650 | Young et al. | Jan 2020 | A1 |
20200022844 | Blott et al. | Jan 2020 | A1 |
20200023102 | Powell | Jan 2020 | A1 |
20200023103 | Joshi et al. | Jan 2020 | A1 |
20200023104 | Eriksson et al. | Jan 2020 | A1 |
20200023105 | Long et al. | Jan 2020 | A1 |
20200023106 | Carroll et al. | Jan 2020 | A1 |
20200030153 | Johannison et al. | Jan 2020 | A1 |
20200030480 | Choi | Jan 2020 | A1 |
20200030499 | Menon et al. | Jan 2020 | A1 |
20200038023 | Dunn | Feb 2020 | A1 |
20200038249 | Pratt et al. | Feb 2020 | A1 |
20200038250 | Edwards et al. | Feb 2020 | A1 |
20200038251 | Locke et al. | Feb 2020 | A1 |
20200038252 | Spiro | Feb 2020 | A1 |
20200038283 | Hall et al. | Feb 2020 | A1 |
20200038470 | Datt et al. | Feb 2020 | A1 |
20200038544 | Grover et al. | Feb 2020 | A1 |
20200038546 | Dizio et al. | Feb 2020 | A1 |
20200038639 | Patel et al. | Feb 2020 | A1 |
20200046565 | Barta et al. | Feb 2020 | A1 |
20200046566 | Carey et al. | Feb 2020 | A1 |
20200046567 | Carroll et al. | Feb 2020 | A1 |
20200046568 | Sexton | Feb 2020 | A1 |
20200046663 | Murdock et al. | Feb 2020 | A1 |
20200046876 | Liu | Feb 2020 | A1 |
20200046887 | Runquist et al. | Feb 2020 | A1 |
20200054491 | Hentrich et al. | Feb 2020 | A1 |
20200054781 | Weiser et al. | Feb 2020 | A1 |
20200060879 | Edwards et al. | Feb 2020 | A1 |
20200061253 | Long et al. | Feb 2020 | A1 |
20200061254 | Joshi et al. | Feb 2020 | A1 |
20200061379 | Bogie et al. | Feb 2020 | A1 |
20200069183 | Rice et al. | Mar 2020 | A1 |
20200069476 | Randolph et al. | Mar 2020 | A1 |
20200069477 | Holm et al. | Mar 2020 | A1 |
20200069478 | Jabbarzadeh et al. | Mar 2020 | A1 |
20200069479 | Buan et al. | Mar 2020 | A1 |
20200069835 | Hissink et al. | Mar 2020 | A1 |
20200069850 | Beadle et al. | Mar 2020 | A1 |
20200069851 | Blott et al. | Mar 2020 | A1 |
20200069853 | Hall et al. | Mar 2020 | A1 |
20200078223 | Locke et al. | Mar 2020 | A1 |
20200078224 | Carroll et al. | Mar 2020 | A1 |
20200078225 | Grillitsch et al. | Mar 2020 | A1 |
20200078305 | Auvinen et al. | Mar 2020 | A1 |
20200078330 | Gay | Mar 2020 | A1 |
20200078482 | Yoon et al. | Mar 2020 | A1 |
20200078499 | Gadde et al. | Mar 2020 | A1 |
20200085625 | Bellini et al. | Mar 2020 | A1 |
20200085626 | Braga et al. | Mar 2020 | A1 |
20200085629 | Locke et al. | Mar 2020 | A1 |
20200085630 | Robinson et al. | Mar 2020 | A1 |
20200085632 | Locke et al. | Mar 2020 | A1 |
20200085991 | Coomber | Mar 2020 | A1 |
20200085992 | Locke et al. | Mar 2020 | A1 |
20200086014 | Locke et al. | Mar 2020 | A1 |
20200086017 | Jardret et al. | Mar 2020 | A1 |
20200086049 | Park et al. | Mar 2020 | A1 |
20200093646 | Locke et al. | Mar 2020 | A1 |
20200093756 | Sabacinski | Mar 2020 | A1 |
20200093953 | Kim et al. | Mar 2020 | A1 |
20200093954 | Leise, III | Mar 2020 | A1 |
20200093970 | Hunt et al. | Mar 2020 | A1 |
20200095421 | Kettel | Mar 2020 | A1 |
20200100945 | Albert et al. | Apr 2020 | A1 |
20200101192 | Folwarzny | Apr 2020 | A1 |
20200107964 | Locke et al. | Apr 2020 | A1 |
20200107965 | Greener | Apr 2020 | A1 |
20200107966 | Francis | Apr 2020 | A1 |
20200107967 | Holm et al. | Apr 2020 | A1 |
20200108169 | Hu et al. | Apr 2020 | A1 |
20200113741 | Rehbein et al. | Apr 2020 | A1 |
20200114039 | Wang et al. | Apr 2020 | A1 |
20200114040 | Waite et al. | Apr 2020 | A1 |
20200114049 | Wall | Apr 2020 | A1 |
20200121509 | Locke et al. | Apr 2020 | A1 |
20200121510 | Hartwell et al. | Apr 2020 | A1 |
20200121513 | Townsend et al. | Apr 2020 | A1 |
20200121521 | Daniel et al. | Apr 2020 | A1 |
20200121833 | Askem et al. | Apr 2020 | A9 |
20200129338 | Gardiner et al. | Apr 2020 | A1 |
20200129341 | Coulthard et al. | Apr 2020 | A1 |
20200129648 | Drury et al. | Apr 2020 | A1 |
20200129654 | Bouvier et al. | Apr 2020 | A1 |
20200129655 | Gardiner et al. | Apr 2020 | A1 |
20200129675 | Robinson et al. | Apr 2020 | A1 |
20200138754 | Johnson | May 2020 | A1 |
20200139002 | Dudnyk et al. | May 2020 | A1 |
20200139023 | Haggstrom et al. | May 2020 | A1 |
20200139025 | Robinson et al. | May 2020 | A1 |
20200141031 | Kosan et al. | May 2020 | A1 |
20200146894 | Long et al. | May 2020 | A1 |
20200146896 | Rice et al. | May 2020 | A1 |
20200146897 | Locke et al. | May 2020 | A1 |
20200146899 | Pratt et al. | May 2020 | A1 |
20200155355 | Hill et al. | May 2020 | A1 |
20200155358 | Wheldrake | May 2020 | A1 |
20200155359 | Carroll et al. | May 2020 | A1 |
20200155361 | Pigg et al. | May 2020 | A1 |
20200155379 | Shaw et al. | May 2020 | A1 |
20200163802 | Hunt et al. | May 2020 | A1 |
20200163803 | Pigg et al. | May 2020 | A1 |
20200164112 | Kato et al. | May 2020 | A1 |
20200164120 | Jaecklein et al. | May 2020 | A1 |
20200170841 | Waite et al. | Jun 2020 | A1 |
20200170842 | Locke | Jun 2020 | A1 |
20200170843 | Collinson et al. | Jun 2020 | A1 |
20200171197 | Hubbell et al. | Jun 2020 | A1 |
20200179300 | Urban et al. | Jun 2020 | A1 |
20200179558 | Munro et al. | Jun 2020 | A1 |
20200179673 | Wan | Jun 2020 | A1 |
20200188179 | Bugedo-Albizuri et al. | Jun 2020 | A1 |
20200188180 | Akbari et al. | Jun 2020 | A1 |
20200188182 | Sanders et al. | Jun 2020 | A1 |
20200188183 | Hamerslagh et al. | Jun 2020 | A1 |
20200188550 | Dagger et al. | Jun 2020 | A1 |
20200188564 | Dunn | Jun 2020 | A1 |
20200190310 | Meyer | Jun 2020 | A1 |
20200197227 | Locke et al. | Jun 2020 | A1 |
20200197228 | Hartwell | Jun 2020 | A1 |
20200197559 | Bourdillon et al. | Jun 2020 | A1 |
20200197580 | Kilpadi et al. | Jun 2020 | A1 |
20200206035 | Kantor et al. | Jul 2020 | A1 |
20200206036 | Robinson et al. | Jul 2020 | A1 |
20200214637 | Brownhill et al. | Jul 2020 | A1 |
20200214897 | Long et al. | Jul 2020 | A1 |
20200214898 | Waite et al. | Jul 2020 | A1 |
20200214899 | Locke et al. | Jul 2020 | A1 |
20200215220 | Schomburg et al. | Jul 2020 | A1 |
20200215226 | Kitagawa et al. | Jul 2020 | A1 |
20200222469 | Cotton | Jul 2020 | A1 |
20200229983 | Robinson et al. | Jul 2020 | A1 |
20200230283 | Yang et al. | Jul 2020 | A1 |
20200237562 | Rice et al. | Jul 2020 | A1 |
20200237564 | Hammond et al. | Jul 2020 | A1 |
20200237816 | Lait | Jul 2020 | A1 |
20200246190 | Luckemeyer et al. | Aug 2020 | A1 |
20200246191 | Lu et al. | Aug 2020 | A1 |
20200246194 | Gonzalez et al. | Aug 2020 | A1 |
20200246195 | Robinson et al. | Aug 2020 | A1 |
20200253785 | Bernet et al. | Aug 2020 | A1 |
20200253786 | Harrison et al. | Aug 2020 | A1 |
20200253788 | Rehbein et al. | Aug 2020 | A1 |
20200254139 | Phillips et al. | Aug 2020 | A1 |
20200261275 | Manwaring et al. | Aug 2020 | A1 |
20200261276 | Lujan Hernandez et al. | Aug 2020 | A1 |
20200268560 | Harrison et al. | Aug 2020 | A1 |
20200268561 | Locke et al. | Aug 2020 | A1 |
20200269028 | Hegg | Aug 2020 | A1 |
20200270484 | Lipscomb et al. | Aug 2020 | A1 |
20200276055 | Randolph et al. | Sep 2020 | A1 |
20200276058 | Locke et al. | Sep 2020 | A1 |
20200277450 | Silverstein et al. | Sep 2020 | A1 |
20200281519 | Gowans et al. | Sep 2020 | A1 |
20200281529 | Grubb et al. | Sep 2020 | A1 |
20200281678 | Long et al. | Sep 2020 | A1 |
20200281775 | Kushnir et al. | Sep 2020 | A1 |
20200282100 | Gil et al. | Sep 2020 | A1 |
20200282114 | Long et al. | Sep 2020 | A1 |
20200282115 | Gardner et al. | Sep 2020 | A1 |
20200289328 | Luckemeyer et al. | Sep 2020 | A1 |
20200289347 | Gowans et al. | Sep 2020 | A1 |
20200289701 | Hall et al. | Sep 2020 | A1 |
20200289712 | Jiang et al. | Sep 2020 | A1 |
20200289723 | Gregory et al. | Sep 2020 | A1 |
20200289726 | Locke et al. | Sep 2020 | A1 |
20200289727 | Locke | Sep 2020 | A1 |
20200289806 | Locke et al. | Sep 2020 | A1 |
20200297541 | Hartwell et al. | Sep 2020 | A1 |
20200297543 | Rodzewicz et al. | Sep 2020 | A1 |
20200297544 | Moine et al. | Sep 2020 | A1 |
20200297892 | Silcock | Sep 2020 | A1 |
20200297893 | Ericson | Sep 2020 | A1 |
20200297894 | Koyama et al. | Sep 2020 | A1 |
20200299865 | Bonnefin et al. | Sep 2020 | A1 |
20200306089 | Delury et al. | Oct 2020 | A1 |
20200306091 | Lee et al. | Oct 2020 | A1 |
20200306094 | Kushnir et al. | Oct 2020 | A1 |
20200315853 | Waite | Oct 2020 | A1 |
20200315854 | Simmons et al. | Oct 2020 | A1 |
20200316271 | Lin | Oct 2020 | A1 |
20200323692 | Locke et al. | Oct 2020 | A1 |
20200324015 | Kettel et al. | Oct 2020 | A1 |
20200330283 | Locke et al. | Oct 2020 | A1 |
20200330284 | Locke et al. | Oct 2020 | A1 |
20200330285 | Rehbein et al. | Oct 2020 | A1 |
20200330658 | Fujisaki | Oct 2020 | A1 |
20200330660 | Patel et al. | Oct 2020 | A1 |
20200337719 | Ingram et al. | Oct 2020 | A1 |
20200337904 | Waite | Oct 2020 | A1 |
20200337905 | Earl et al. | Oct 2020 | A1 |
20200337906 | Long et al. | Oct 2020 | A1 |
20200337908 | Long et al. | Oct 2020 | A1 |
20200338228 | Kharkar et al. | Oct 2020 | A1 |
20200338243 | Harrison et al. | Oct 2020 | A1 |
Number | Date | Country |
---|---|---|
2745059 | Jun 2010 | CA |
101076251 | Nov 2007 | CN |
101331263 | Dec 2008 | CN |
105407930 | Mar 2016 | CN |
0616650 | Sep 1994 | EP |
0680344 | Nov 1995 | EP |
1158859 | Dec 2001 | EP |
1318842 | Jun 2003 | EP |
1343510 | Sep 2003 | EP |
1425050 | Jun 2004 | EP |
1557088 | Jul 2005 | EP |
1882482 | Jan 2008 | EP |
1925719 | May 2008 | EP |
1343510 | May 2010 | EP |
2262545 | Dec 2010 | EP |
2996730 | Mar 2016 | EP |
3187204 | Jul 2017 | EP |
3241439 | Nov 2017 | EP |
3643328 | Apr 2020 | EP |
3643330 | Apr 2020 | EP |
3643331 | Apr 2020 | EP |
3669838 | Jun 2020 | EP |
3669843 | Jun 2020 | EP |
3669844 | Jun 2020 | EP |
2604900 | Apr 1988 | FR |
735462 | Aug 1955 | GB |
1105829 | Mar 1968 | GB |
2094802 | Sep 1982 | GB |
2220881 | Jan 1990 | GB |
2579211 | Jun 2020 | GB |
2579368 | Jun 2020 | GB |
S5138427 | Mar 1976 | JP |
H04282311 | Oct 1992 | JP |
H0782121 | Mar 1995 | JP |
H07502081 | Mar 1995 | JP |
H08505790 | Jun 1996 | JP |
2000510539 | Aug 2000 | JP |
2003052725 | Feb 2003 | JP |
2003510475 | Mar 2003 | JP |
2003512095 | Apr 2003 | JP |
2003531828 | Oct 2003 | JP |
2005210997 | Aug 2005 | JP |
2007501683 | Feb 2007 | JP |
2007509034 | Apr 2007 | JP |
2007167266 | Jul 2007 | JP |
2007167266 | Jul 2007 | JP |
2007532606 | Nov 2007 | JP |
2008502735 | Jan 2008 | JP |
2008038293 | Feb 2008 | JP |
2008503557 | Feb 2008 | JP |
2008507327 | Mar 2008 | JP |
2008526997 | Jul 2008 | JP |
2009519312 | May 2009 | JP |
2010508346 | Mar 2010 | JP |
2010155963 | Jul 2010 | JP |
2012512857 | Jun 2012 | JP |
2016040294 | Mar 2016 | JP |
2016519966 | Jul 2016 | JP |
100868574 | Nov 2008 | KR |
2092180 | Oct 1997 | RU |
WO-8401721 | May 1984 | WO |
WO-9218098 | Oct 1992 | WO |
WO-9312275 | Jun 1993 | WO |
WO-9319152 | Sep 1993 | WO |
WO-9402022 | Feb 1994 | WO |
WO-9416746 | Aug 1994 | WO |
WO-9601119 | Jan 1996 | WO |
WO-9702313 | Jan 1997 | WO |
WO-9806260 | Feb 1998 | WO |
WO-9846818 | Oct 1998 | WO |
WO-0054593 | Sep 2000 | WO |
WO-0072874 | Dec 2000 | WO |
WO-0123653 | Apr 2001 | WO |
WO-0124839 | Apr 2001 | WO |
WO-0128338 | Apr 2001 | WO |
WO-0128600 | Apr 2001 | WO |
WO-0137936 | May 2001 | WO |
WO-0162289 | Aug 2001 | WO |
WO-0243743 | Jun 2002 | WO |
WO-02055060 | Jul 2002 | WO |
WO-02078755 | Oct 2002 | WO |
WO-03022317 | Mar 2003 | WO |
WO-03047341 | Jun 2003 | WO |
WO-03068247 | Aug 2003 | WO |
WO-2004028461 | Apr 2004 | WO |
WO-2004035718 | Apr 2004 | WO |
WO-2004056346 | Jul 2004 | WO |
2004105809 | Dec 2004 | WO |
WO-2004108093 | Dec 2004 | WO |
2005018543 | Mar 2005 | WO |
WO-2005020915 | Mar 2005 | WO |
WO-2005032459 | Apr 2005 | WO |
WO-2005079582 | Sep 2005 | WO |
WO-2005099757 | Oct 2005 | WO |
WO-2005123103 | Dec 2005 | WO |
WO-2006000765 | Jan 2006 | WO |
WO-2006015317 | Feb 2006 | WO |
WO-2006022970 | Mar 2006 | WO |
WO-2006029213 | Mar 2006 | WO |
WO-2006111624 | Oct 2006 | WO |
WO-2007005720 | Jan 2007 | WO |
WO-2007068938 | Jun 2007 | WO |
WO-2008035734 | Mar 2008 | WO |
WO-2009130608 | Oct 2009 | WO |
WO-2010070292 | Jun 2010 | WO |
2011121394 | Oct 2011 | WO |
2011135284 | Nov 2011 | WO |
2011144888 | Nov 2011 | WO |
WO-2012061225 | May 2012 | WO |
WO-2012072980 | Jun 2012 | WO |
WO-2012136968 | Oct 2012 | WO |
2013015827 | Jan 2013 | WO |
2013126049 | Aug 2013 | WO |
2014014842 | Jan 2014 | WO |
WO-2014186590 | Nov 2014 | WO |
2015145117 | Oct 2015 | WO |
2015173546 | Nov 2015 | WO |
2016141450 | Sep 2016 | WO |
2017016974 | Feb 2017 | WO |
2017125250 | Jul 2017 | WO |
2018029231 | Feb 2018 | WO |
2018094061 | May 2018 | WO |
2018162613 | Sep 2018 | WO |
2018163093 | Sep 2018 | WO |
2018189265 | Oct 2018 | WO |
2018226667 | Dec 2018 | WO |
2018227144 | Dec 2018 | WO |
2018231825 | Dec 2018 | WO |
2018236648 | Dec 2018 | WO |
2019002085 | Jan 2019 | WO |
2019012068 | Jan 2019 | WO |
2019012069 | Jan 2019 | WO |
2019022493 | Jan 2019 | WO |
2019027933 | Feb 2019 | WO |
2019038548 | Feb 2019 | WO |
2019038549 | Feb 2019 | WO |
2019040656 | Feb 2019 | WO |
2019050855 | Mar 2019 | WO |
2019058373 | Mar 2019 | WO |
2019073326 | Apr 2019 | WO |
2019083563 | May 2019 | WO |
2019083868 | May 2019 | WO |
2019086911 | May 2019 | WO |
2019091150 | May 2019 | WO |
2019094147 | May 2019 | WO |
2019096828 | May 2019 | WO |
2019113275 | Jun 2019 | WO |
2019113623 | Jun 2019 | WO |
2019191590 | Oct 2019 | WO |
2019193141 | Oct 2019 | WO |
2019193333 | Oct 2019 | WO |
2019199389 | Oct 2019 | WO |
2019199596 | Oct 2019 | WO |
2019199687 | Oct 2019 | WO |
2019199798 | Oct 2019 | WO |
2019199849 | Oct 2019 | WO |
2019200035 | Oct 2019 | WO |
2019215572 | Nov 2019 | WO |
2019219613 | Nov 2019 | WO |
2019234365 | Dec 2019 | WO |
2020005344 | Jan 2020 | WO |
2020005536 | Jan 2020 | WO |
2020005546 | Jan 2020 | WO |
2020005577 | Jan 2020 | WO |
2020007429 | Jan 2020 | WO |
2020011691 | Jan 2020 | WO |
2020014178 | Jan 2020 | WO |
2020014310 | Jan 2020 | WO |
2020018300 | Jan 2020 | WO |
2020605062 | Jan 2020 | WO |
2020026061 | Feb 2020 | WO |
2020026144 | Feb 2020 | WO |
2020033351 | Feb 2020 | WO |
2020035811 | Feb 2020 | WO |
2020043665 | Mar 2020 | WO |
2020044237 | Mar 2020 | WO |
2020046443 | Mar 2020 | WO |
2020047255 | Mar 2020 | WO |
2020049038 | Mar 2020 | WO |
2020055945 | Mar 2020 | WO |
2020056014 | Mar 2020 | WO |
2020056182 | Mar 2020 | WO |
2020065531 | Apr 2020 | WO |
2020070231 | Apr 2020 | WO |
2020074512 | Apr 2020 | WO |
2020078993 | Apr 2020 | WO |
2020079009 | Apr 2020 | WO |
2020079330 | Apr 2020 | WO |
2020081259 | Apr 2020 | WO |
2020081391 | Apr 2020 | WO |
2020092598 | May 2020 | WO |
2020136555 | Jul 2020 | WO |
2020141059 | Jul 2020 | WO |
2020144347 | Jul 2020 | WO |
2020159548 | Jul 2020 | WO |
2020159675 | Aug 2020 | WO |
2020159677 | Aug 2020 | WO |
2020159678 | Aug 2020 | WO |
2020159823 | Aug 2020 | WO |
2020159859 | Aug 2020 | WO |
2020159892 | Aug 2020 | WO |
2020161086 | Aug 2020 | WO |
2020173665 | Sep 2020 | WO |
2020173760 | Sep 2020 | WO |
2020174264 | Sep 2020 | WO |
2020174510 | Sep 2020 | WO |
Entry |
---|
510(k) Premarket Notification, AQUACEL and AQUACEL Ag, Section 5: 510(k) Summary revised Apr. 21, 2008, 6 pages. |
AMR: a major European and Global challenge: fact sheet. Antimicrobial Resistance—European Commission (EC—AMR) Sep. 8, 2017. https://ec.europa.eu/health/amr/sites/amr/files/amr_factsheet_en.pdf. Accessed Jul. 2, 2018. |
Anwar H, Dasgupta M, Costerton J. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990; 34: 2043-2046. |
Arata, J. Staphylococcus aureus and the skin. Japanese Journal of Chemotherapy, 49(3):147-156, 2001. |
Australia Patent Application No. 2014265336 Examiner's First Report dated Mar. 29, 2017. |
Australian Patent Application No. 2013366038 Examination Report No. 2 dated Jun. 19, 2018. |
Australian Patent Application No. 2017201084 Examination Report No. 1 dated May 18, 2018. |
Australian Patent Application No. 2014265336 Second Examination Report dated Mar. 26, 2018. |
Banin et al., Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Applied and Environmental Microbiology, 72(3):2064-2069, 2006. |
Bay L, Kragh K, Eickhardt S, et al. Bacterial aggregates establish at the edges of acute epidermal wounds. Adv Wound Care. 2018; 7: 105-13. |
Bohn G, Liden B, Schultz G, et al. Ovine-based collagen matrix dressing: Next-generation collagen dressing for wound care. Adv Wound Care. 2016; 5: 1-10. |
Bowler et al., Dressing conformability and silver-containing wound dressings. Wounds U.K., 6:14-20 (2010). |
Bowler P. Antibiotic resistance and biofilm tolerance: a combined threat in the treatment of chronic infections. J Wound Care. 2018 27: 273-277. |
Bowler P, Jones S, Davies B, Coyle E. Infection control properties of some wound dressings. J Wound Care. 1999; 8: 499-502. |
Bowler P, Jones S, Towers V, et al. Dressing conformability and silver-containing wound dressings. Wounds UK. 2010; 6: 14-20. |
Bowler P, Parsons D. Combatting wound biofilm and recalcitrance with a novel anti-biofilm Hydrofiber® wound dressing. Wound Medicine. 2016; 14: 6-11. |
Bryant R, Nix D. Principles for practice development to facilitate outcomes and productivity. In Bryant R and Nix D, eds. Acute and Chronic Wounds: Current Management Concepts. 5th ed. St. Louis, MO: Elsevier; 2016: 1-20. |
Canadian Patent Application No. 2834871 Office Action dated Oct. 1, 2018. |
Canadian Patent Application No. 2,745,059 Office Action dated Apr. 20, 2018. |
Canadian Patent Application No. 2,745,059 Office Action dated Aug. 2, 2017. |
Canadian Patent Application No. 2,745,059 Office Action dated Dec. 17, 2018. |
Canadian Patent Application No. 2,745,059 Office Action dated Oct. 25, 2016. |
Canadian Patent Application No. 2,819,303 Office Action dated Oct. 24, 2017. |
Canadian Patent Application No. 2,834,871 Office Action dated Jan. 31, 2018. |
Capinera et al., Insectional activity of photoactive dyes to American and migratory grasshoppers (Orthoptera acrididae). J.Econ.Entomol., 92(3):662-666, 2000. |
Cavaliere R, Ball J, Turnbull L, Whitchurch C. The biofilm matrix destabilizers, EDTA and DNasel, enhance the susceptibility of nontypeable Hemophilus influenzae biofilms to treatment with ampicillin and ciprofloxacin. Microbiology. 2014; 3: 557-67. |
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. 2013. http://www.cdc.gov/ drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed Aug. 1, 2018. |
Ceri et al., The Calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. Journal of Clinical Microbiology, 37(6):1771-1776, 1999. |
Chan B, Cadarette S, Wodchis W, Wong J, Mittmann N, Kran M. Cost-of-illness studies in chronic ulcers: A systemic review. J Wound Care. 2017; 26: S4-S15. |
Chemburu et al., Light-induced biocidal action of conjugated polyelectrolytes supported on colloids Langmuir, 24:11053-11062 (2008). |
Chile Patent Application No. 3274-2015 Office Action dated Jun. 20, 2017. |
Chile Patent Application No. 3274-2015 second Office Action dated Jan. 22, 2018. |
Chinese Patent Application No. 201180066375.2 Reexamination Notice dated Jul. 3, 2017. |
Chinese Patent Application No. 201180066375.2 Office Action dated Sep. 26, 2016. |
Chinese Patent Application No. 201180066375.2 Reexamination Decision dated Dec. 20, 2017. |
Chinese Patent Application No. 201280027537.6 Chinese Third Office Action dated Mar. 2, 2016. |
Chinese Patent Application No. 201280027537,6 Decision of Reexamination dated Oct. 27, 2017. |
Chinese Patent Application No. 201280027537.6 Office Action dated Sep. 12, 2016. |
Chinese Patent Application No. 201280027537.6 Reexamination Notice dated Jun. 8, 2017. |
Chinese Patent Application No. 201380073403.2 Third Office Action dated Mar. 26, 2018. |
Chinese Patent Application No. 201480028155.4 Decision on Rejection dated Nov. 21, 2018. |
Chinese Patent Application No. 201480028155.4 First Office Action dated Apr. 18, 2017. |
Chinese Patent Application No. 201480028155.4 Office Action dated Mar. 22, 2018. |
Ciofu O, Rojo-Molinero E, Macia M, Oliver A. Antibiotic treatment of biofilm infections. APMIS. 2017; 125: 304-19. |
Costerton J, Geesey G, Cheng K. How bacteria stick. Sci Am. 1978; 238: 86-95. |
Costerton J, Irvin R, Cheng K. The bacterial glycocalyx in nature and disease. Ann Rev Microbiol. 1981; 35: 299-324. |
Costerton J, Stewart P, Greenberg E. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284: 1318-22. |
Costerton JW. Bacterial biofilms in nature and disease. Ann Rev Microbiol. 1987; 41: 435-64. |
Database Biosis, Biosciences Information Service, Philadelphia, PA, 1992, Kida N., et al., “Effect of PH on Preferential Antibacterial Activity of Ethylenediaminetetraacetic Acid EDTA”, XP002485724, Database Accession No. PREV199294118093. |
Database Biosis, Biosciences Information Service, Philadelphia, PA, 2005, Percival, L, etal., “Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm”, XP002485725, Database Accession No. PREV200600021247. |
Database CA, Chemical Abstracts Service, Columbus, Ohio, US; Izzat, I.N., et al., “Effect of varying concentrations o EDTA on the antimicrobial properties of cutting fluid preservatives”, 1979, XP002485722, STN-International Database Accession No. 93:62380. |
Database CA, Chemical Abstracts Service, Columbus, Ohio, US; Reybrouck, G., et al., “Effect of ethylenediaminetetraacetate on the germicidal action of disinfectants against Pseudomonas aeruginosa”, XP002485721, STN-International Database Accession No. 72:11588, 1969. |
Database Medline, US National Library of Medicine, Bethesda, MD, 1988, Kaur, P., et al., “Effect of certain chelating agents on the antibacterial action of silver nitrate”, XP002485723, Database Accession No. NLM3143759. |
Demidova and Hamblin, Photodynamic therapy targeted to pathogens Int. J. Immunopathol Pharmacol., 17(3):245-254, 2004. |
Dini V, Salvo P, Janowska A, Di Francesco F, Barbini A, Romanelli M. Correlation between wound temperature obtained with an infrared camera and clinical wound bed score in venous leg ulcers. Wounds. 2015; 27: 274-8. |
Dougherty et al., Photodynamic therapy. Journal of the National Cancer Institute, 90(12): 889-905, 1998. |
Doughty D, Sparks B. Wound healing physiology and factors that affect the wound repair process. In Bryant R and Nix D, eds. Acute and Chronic Wounds: Current Management Concepts. 5th ed. St. Louis, MO: Elsevier; 2016: 63-81. |
Eming S, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med. 2014; 6: 57-72. doi: 10.1126/scitranslmed.3009337. |
Etebu E, Arikekpar I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspective. Int J of Appl Microbiol and Biothech Res. 2016; 4: 90-101. http://www.bluepenjournals.org/ijambr/pdf/2016/October/Etebu_and_Arikekpar.pdf. Accessed Aug. 8, 2018. |
European Centre for Disease Prevention and Control (ECDC). Proposals for EU Guidelines on the Prudent Use of Antimicrobials in Humans. Stockholm: ECDC; 2017. http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1643. Accessed Jul. 2, 2018. |
European Patent Application No. 09795521.5 Communication dated Mar. 24, 2017. |
European Patent Application No. 09795521.5 Office Action dated May 9, 2018. |
European Patent Application No. 12719420.7 Communication dated Jul. 20, 2016. |
European Patent Application No. 12719420.7 Examination Report dated Apr. 5, 2017. |
European Patent Application No. 12719420.7 Examination Report dated Aug. 7, 2018. |
European Patent Application No. 13821122.2 Communication dated Oct. 30, 2017. |
European Patent Application No. 14797983.5 Supplementary European Search Report dated Dec. 6, 2016. |
European Patent Application No. 17163418.1 extended European Search Report dated Sep. 17, 2017. |
European Patent Application No. EP 06820530.1 Communication dated Apr. 7, 2016. |
European Patent Application No. EP 06820530.1 Communication dated Jan. 30, 2013. |
European Patent Application No. EP 06820530.1 Communication dated Mar. 30, 2009. |
FDA website on Medical Devices, Premarket Notification (510k), 4 pages, 2013. |
Fife C, Carter M, Walker D, Thomson B. Wound care outcomes and associated cost among patients treated in US outpatient wound centers: Data from the US Wound Registry. Wounds. 2012; 24: 10-7. |
Finnegan S, Percival S. EDTA: an antimicrobial and antibiofilm agent for use in wound care. Adv Wound Care. 2015; 4: 415-21. |
Fleming D, Rumbaugh K. Approaches to dispersing medical biofilms. Microorganisms. 2017; 5: 1-16. |
Frykberg R, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care. 2015; 4: 560-82. |
Gardner S, Frantz R, Doebbeling B. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. Wound Repair Regen. 2001; 9: 178-86. |
Gardner S, Hillis S, Frantz R. Clinical signs of infection in diabetic foot ulcers with high microbial load. Biol Res Nurs. 2009; 11: 119-28. |
Gilbert, et al., The Use of Poloxamer Hydrogels for the Assessment of Biofilm Susceptibility Towards Biocide Treatments, Journal of Applied Microbiology, 85:985-990, 1998. |
Gilchrist M, Seaton R. Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists. J Antimicrob Chemother. 2015; 70: 965-70. |
Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg. 2004; 187: S38-S43. |
Gottrup F, Apelqvist J, Bjarnsholt T, et al. Antimicrobials and non-healing wounds: Evidence, controversies and suggestions—key messages. J Wound Care. 2014; 23: 477-8, 480, 482. |
Guest JF, Vowden K. The health economic burden that acute and chronic wounds impose on an average clinical commissioning group/health board in the UK. J Wound Care. 2017; 26: 292-303. |
Harding K, Szczepkowski M, Mikosiński J, et al. Safety and performance evaluation of a next-generation antimicrobial dressing in patients with chronic venous leg ulcers. Int Wound J. 2016; 13: 442-8. |
Harrison-Balestra et al., A wound isolatedPseudomonas aeruginosagrows a biofilm in vitro within 10 hours and is visualized by light microscopy. Dermatol. Surgery, 29(6):631-635, 2003. |
Hobot et al., Effect of Hydrofiber wound dressings on bacterial ultrastructure. J Electron Microsc (Tokyo). 57(2):67-75 (2008). |
Howell J, Stair T, Howell A, Mundt D, Falcone A, Peters S. The effect of scrubbing and irrigation with normal saline, povidone iodine, and cefazolin on wound bacterial counts in a Guinea pig model. Am J Emerg Med. 1993; 11: 134-38. |
Hurlow J, Blanz E, Gaddy J. Clinical investigation of biofilm in non-healing wounds by high resolution microscopy techniques. J Wound Care. 2016; 25(suppl 9): S11-S22. |
Indian Patent Application No. 9392/DELNP/2013 First Examination Report dated Feb. 23, 2018. |
Indian Patent Application No. 5856/DELNP/2013 First Examination Report dated Jun. 20, 2018. |
International Wound Infection Institute (IWII). Wound infection in clinical practice. Wounds International, 2016. http://www. woundinfection-institute.com/wp-content/uploads/2017/03/IWII-Wound-infection-in-clinical-practice.pdf. Accessed Jul. 2, 2018. |
James G, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen. 2008; 16: 37-44. |
Japan Patent Application No. 2016-514095 Office Action dated Feb. 20, 2018. |
Japanese Patent Application No. 2017-112806 Official Action dated Mar. 6, 2018. |
Japanese Patent Application No. 2013-541415 Final Rejection dated Jun. 14, 2016. |
Japanese Patent Application No. 2014-242257 Office Action dated Apr. 5, 2016 (English translation is provided). |
Japanese Patent Application No. 2014-242257 Office Action dated May 23, 2017. |
Japanese Patent Application No. 2014-543972 Office Action dated Dec. 20, 2016. |
Japanese Patent Application No. 2015-200279 Office Action dated Aug. 31, 2017. |
Japanese Patent Application No. 2015-200279 Office Action dated Feb. 7, 2017. |
Japanese Patent Application No. 2015-200279 Office Action dated Jul. 12, 2016. |
Japanese Patent Application No. 2015-548762 Office Action dated Jul. 31, 2018. |
Japanese Patent Application No. 2015-548762 Office Action dated Oct. 10, 2017. |
Japanese Patent Application No. 2016-154639 Office Action dated Jun. 8, 2017. |
Japanese Patent Application No. 2016-202835 Office Action dated Jun. 20, 2017. |
Japanese Patent Application No. 2016-202835 Office Action dated Mar. 6, 2018. |
Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance—a threat to the world's sustainable development. Upsala J Med Sci. 2016; 121: 159-64. |
Johani K, Malone M, Jensen S, et al. Microscopy visualisation confirms multi-species biofilms are ubiquitous in diabetic foot ulcers. Int Wound J. 2017; 14: 1160-9. |
Jones et al., Antimicrobial activity of silver-containing dressings is influenced by dressing conformability with a wound surface. Wounds, 17:263-270 (2005). |
Kapoor et al., Fluorescence and absorption spectra of Rose-Bengal dye in the presence of surfactants. Journal of Luminescence, 22(4):429-439, 1981. (Abstract only). |
Kaur and Vadehra, Effect of certain chelating agents on the antibacterial action of silver nitrate. Journal of Hygiene, Epidemiology, Microbiology, and Immunology, 32(3):299-306, 1988. (retrieved from Medline, NLM3143759). |
Keast D, Swanson T, Carville K, Fletcher J, Schultz G, Black J. Ten top tips . . . understanding and managing wound biofilm. Wounds International. 2014; 5: 20-3. |
Kharkevich, D.A., Pharmacology:Textbook. Geotar-Media, p. 66-71, 2006. |
Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti, M, Hakaim A. Clinical assessment of a biofilm-disrupting agent for the management of chronic wounds compared with standard of care: a therapeutic approach. Wounds. 2018; 30: 120-30. |
Kita et al., pH-Dependent preferential antibacterial activity of Ethylenediaminetetraacetic acid (EDTA). Japanese Journal of Bacteriology, 47(4):6 pages, 1992. |
Kite et al., Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol., 42.7 (2004): 3073-3076. |
Kryukov et al., the role of bacteriological examination in diagnosis of chronic tonsillitis. Becthnk 3:35-38, 2008. |
Lazarus G, Cooper D, Knighton D, Percoraro R, Rodeheaver G, Robson M. Definitions and guidelines for assessment of wounds and evaluation of healing. Wound Repair Regen. 1994; 2: 165-70. |
Lewis K. Persister cells. Ann Rev Microbiol. 2010; 64: 357-72. |
Lineaweaver et al., Topical antimicrobial toxicity. Arch Surg., 120(3):267-70 (1985). |
Lipsky B, Aragón-Sánchez J, Diggle M, et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev. 2016; 32: 45-74. |
Lipsky B, Dryden M, Gottrup F, et al. Antimicrobial stewardship in wound care: A position paper from the British society for antimicrobial chemotherapy and European wound management association. J Antimicrob Chemother 2016; 71: 3026-35. |
Lipsky B. Medical treatment of diabetic foot infections. Clin Infect Dis. 2004; 39: S104-S114. |
Lipsky B, Peters E, Senneville E, et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev. 2012; 28(suppl 1): 163-78. |
Macia M, Roho-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014; 20: 981-90. |
Malone M, Bjarnsholt T, McBain A, et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017; 26: 20-5. |
McDonnell G, Russell A. Antiseptics and disinfectants: Activity, action, and resistance. Clin Microbiol Rev. 1999; 12: 147-79. |
Meredith K, Burke N, Brownley H, et al. Antimicrobial efficacy of enhanced and standard silver wound dressings in an in vitro mature bioburden model. Symposium on Advanced Wound Care. 2018 Poster presentation: Las Vegas. |
Metcalf D, Bowler P. Biofilm delays wound healing: A review of the evidence. Burns Trauma. 2013; 1: 5-12. |
Metcalf D, Bowler P. Clinical Impact of an enhanced antimicrobial dressing in non-healing wounds previously managed with antibiotics. Symposium on Advanced Wound Care. 2018 Poster presentation: Las Vegas. |
Metcalf D, Bowler P, Parsons D. In: Dhanasekaran D, ed. Wound Biofilm and Therapeutic Strategies, Microbial Biofilms—Importance and Applications. Rijeka, Croatia: InTech; 2016. https://www.intechopen.com/books/microbial-biofilms-importance-and-applications/wound-biofilm-and-therapeutic-strategies. Accessed Aug. 8, 2018. |
Metcalf D, Parsons D, Bowler P. A next-generation antimicrobial wound dressing: a real-life clinical evaluation in the UK and Ireland. J Wound Care. 2016; 25: 132-8. |
Metcalf D, Parsons D, Bowler P. Clinical safety and effectiveness evaluation of a new antimicrobial wound dressing designed to manage exudate, infection and biofilm. Int Wound J. 2017; 14: 203-13. |
Mexican Patent Application No. MX/a/2013/006090 Official Action dated Jun. 7, 2016. |
Mexican Patent Application No. MX/a/2015/015197 Office Action dated Mar. 2, 2018. |
Muller et al. pH-dependent formation of ethylenediaminetetraacetic acid supramolecular aggregates. FEBS Lett 340:17-21 (1994). |
Nagai et al., Suppressive effects of EDTA for Pseudomonas aeruginosa products biofiim STN CAPLUS, Jan. 1, 1996, 1 page.XP002122029. |
Nagoba B, Suryawanshi N, Wadher B, Selkar S. Acidic environment and wound healing: a review. Wounds. 2015; 27: 5-11. |
Newman G, Walker M, Hobot J, Bowler P. Visualisation of bacterial sequestration and bactericidal activity within hydrating Hydrofiber wound dressings. Biomaterials. 2006; 27: 1129-39. |
Nickel J, Wright J, Ruseska I, Marrie T, Whitfield C, Costerton J. Antibiotic resistance of pseudomonas aeruginosa colonizing a urinary catheter in vitro. Eur J Clin Microbiol. 1985; 4: 213-18. |
Nix D, Pierce B, Haugen V. Eliminating non-compliance. In Bryant R and Nix D, eds. Acute and Chronic Wounds: Current Management Concepts. 5th ed. St. Louis, MO: Elsevier; 2016: 428-40. |
Nussbaum S, Carter M, Fife C, et al. An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds. Value Health. 2018; 21: 27-32. |
Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015; 34: 877-86. |
Ono, N. A Semi-quantitative measurement of glycocalyx and an ATP bioluminescent assay for the analysis of Pseudomonas Aeruginosa biofilm. The Japanese Journal of Urology, 86(9):1440-1449, 1995. |
Ovington, The Value of Silver in Wound Management. Podiatry Today, Dec. 1999, 12(7):59-62. (marked as Exhibit 3 at the Deposition of Fiona Adam). |
Parikh et al., Antimicrobial silver/sodium carboxymethyl cotton dressings for burn wounds Textile Research Journal, 75(2):134-138 (2005). |
Parsons et al., Enhanced Performance and Mode of Action of a Novel Antibiofilm Hydrofiber Wound Dressing. BioMed Research International 2016: ID 7616471:1-14 (2016). |
PCT Patent Application No. PCT/GB2012/000329 International Search Report and Written Opinion dated Jul. 17, 2012. |
PCT Patent Application No. PCT/US2014/038224 International Preliminary Report on Patentability dated Nov. 17, 2015. |
PCT Patent Application No. PCT/US2014/038224 International Search Report dated Sep. 15, 2014. |
PCT Patent Application No. PCT/US2014/038224 Written Opinion dated Sep. 15, 2014. |
PCT/GB2006/004691 International Preliminary Report on Patentability dated Aug. 12, 2008. |
PCT/GB2006/004691 International Search Report dated Jul. 7, 2008. |
PCT/GB2006/004691 Written Opinion dated Jul. 7, 2008. |
PCT/GB2009/002912 International Preliminary Report on Patentability dated Jun. 21, 2011. |
PCT/GB2009/002912 International Search Report and Written Opinion dated Mar. 2, 2010. |
PCT/GB2011/001665 International Preliminary Report on Patentability dated Jun. 4, 2013. |
PCT/GB2011/001665 International Search Report dated Mar. 2, 2012. |
PCT/GB2011/001665 Written Opinion dated Mar. 2, 2012. |
Pennington JA. , A review of iodine toxicity reports. J Am Diet Assoc., 90(11):1571-81 (1990). |
Percival et al., Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infection Control and Hospital Epidemiology, 26(6):515-519, 2005. |
Percival S, Bowler P. Biofilms and their potential role in wound healing. Wounds. 2004; 16: 234-240. |
Petchiappan A, Chatterji D. Antibiotic resistance: Current perspectives. ACS Omega 2017, 2, 7400-7409. https://www.researchgate. net/publication/321019969/download. Accessed Jul. 7, 2018. |
Phillips T. Chronic cutaneous ulcers: Etiology and epidemiology. J Invest Dermatol. 1994; 102: 38S-41S. |
Poon and Burd, In vitro cytotoxity of silver: implication for clinical wound care. Burns. 30(2):140-7 (2004). |
Ramage et al., Inhibition on Candida albicans biofilm formation using divalent cation chelators (EDTA), Mycopathologia, 164:301-306, 2007. |
Reybrouck et al., Effect of ethylenediamine tetraacetate on the germicidal action of disinfectants against “Pseudomona.” Acta Clinica Belgica, 24(1):32-41, 1969. |
Rhoads D, Wolcott R, Percival S. Biofilms in wounds: management strategies. J Wound Care. 2008; 17: 502-9. |
Rodeheaver G, Ratliff C. Wound cleansing, wound irrigation, wound disinfection. In: Krasner D, van Rijswijk L, eds. Chronic Wound Care: The Essentials e-Book. Malvern, PA: HMP; 2018: 47-62. Available at: https://s3.amazonaws.com/whywoundcare/Files/ Chapter+5.pdf. Accessed Jul. 7, 2018. |
Romanelli M, Vowden K, Weir D. Exudate management made easy. Wounds International. 2014. http://www.woundsinternational. com/made-easys/view/exudate-management-made-easy-1. Accessed Jul. 11, 2018. |
Rondas A, Schols J, Stobberingh E, Price P. Definition of infection in chronic wounds by Dutch nursing home physicians. Int Wound J. 2009; 6: 267-74. |
Russian Patent Application No. 2015153446 Office Action and Search Report dated Apr. 23, 2018. |
Russian Patent Application No. 2013129866 Office Action dated Oct. 21, 2016. |
Russian Patent Application No. 2013129866/10 Protocol of a Meeting with the Examiner dated Jun. 14, 2017. |
Russian Patent Application No. 2013149176 Official Action dated Feb. 21, 2018. |
Russian Patent Application No. 2013149176 Official Action dated Jun. 2, 2016. |
Russian Patent Application No. 2015153446 Office Action dated Feb. 10, 2016 (In Russian). |
Said et al., An in vitro test of the efficacy of an anti-biofilm wound dressing.Int J Pharm. 474(1-2):177-181 (2014). |
Saudi Arabia Patent Application No. 515370133 2nd Examination Report dated Feb. 6, 2017. |
Savage V, Chopra I, ONeill A. Staphylococcus aureus biofilms promote horizontal transfer of antibiotic resistance. Antimicrob Agents Chemother. 2013; 57: 1968-70. |
Sen C, Gordillo G, Roy S, et al. Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair Regen. 2009; 17: 763-71. |
Senter, A Textbook of Organic Chemistry, Fifth Ed. 1919, pp. 435-443. |
Seth A, Zhong A, Nguyen K, et al. Impact of a novel, antimicrobial dressing on in vivo, Pseudomonas aeruginosa wound biofilm: quantitative comparative analysis using a rabbit ear model. Wound Repair Regen. 2014; 22: 712-9. |
Shanmugam V, Couch K, McNish S, Amdur R. Relationship between opioid treatment and rate of healing in chronic wounds. Wound Repair Regen. 2017; 25: 120-30. |
Sharma et al., Toluidine blue-mediated photodynamic effects on Staphylococcal biofilms. Antimicrobial Agents and Chemotherapy, 52(1):299-305, 2008. |
Smith & Nephew, Inc., OTC Medication Information: Dermal Wound Cleanser, benzethonium chloride spray. Details from the FDA, via OTCLabels.com, 6 pages, retrieved Jul. 15, 2014. |
Song T, Duperthuy M, Nyunt-Wai, S.Sub-optimal treatment of bacterial biofilms. Antibiotics. 2016; 5: 1-18. |
Spellberg B, Srinivasan A, Chambers H. New societal approaches to empowering antibiotic stewardship. JAMA. 2016; 315: 1229-30. |
Stevens D, Bisno A, Chambers H, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59: 147-59. |
Stewart P. Antimicrobial tolerance in biofilms. Microbiol Spectrum. 2015; 3: 1-30. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4507308/pdf/nihms697879.pdf. Accessed Jul. 24, 2018. |
Stotts R. Wound Bioburden. In Baranoski, S, Ayello, E. eds. Wound Care Essentials: Practice and Principles. Philadelphia, PA: Wolters Klower; 2004: 121-48. |
Swisher, R.D., Surfactant effects on humans and other mammals. The Soap and Detergent Association, Scientific and Technical Report, 4:1-8, 11, 16, 17,19, Nov. 1966. |
Taiwanese Patent Application No. 103117207 Office Action dated Apr. 11, 2018. |
Tallardia. Drug synergism: Its detection and applications. The Journal of Pharmacology and Experimental Therapeutics, 298(3):865-872, 2001. |
Thomas and McCubbin, An in vitro analysis of the antimicrobial properties of 10 silver-containing dressings. The Journal of Wound Care, Sep. 2003, 12(8):105-108. |
Thomas-Hess, C. Checklist for factors affecting wound healing. Adv Skin Wound Care. 2011; 24: 192. |
Torkington-Stokes R, Metcalf D, Bowler P. Management of diabetic foot ulcers: valuation of case studies. Br J Nurs. 2016; 25: S27-S33. |
Understanding biofilms. Bacteriality. Published online May 26, 2008. http://bacteriality.com/2008/05/biofilm/. Accessed Jul. 2, 2018. |
United Nations. World Population Aging. New York. 2017. http://www.un.org/en/development/desa/population/publications/pdf/ageing/WPA2017_Highlights.pdf. Accessed Jul. 24, 2018. |
U.S. Appl. No. 11/610,671 Office Action dated Apr. 2, 2008. |
U.S. Appl. No. 11/610,671 Office Action dated Apr. 7, 2011. |
U.S. Appl. No. 11/610,671 Office Action dated Aug. 17, 2009. |
U.S. Appl. No. 11/610,671 Office Action dated Dec. 3, 2008. |
U.S. Appl. No. 11/610,671 Office Action dated Feb. 18, 2010. |
U.S. Appl. No. 11/610,671 Office Action dated Mar. 11, 2015. |
U.S. Appl. No. 11/610,671 Office Action dated Mar. 20, 2014. |
U.S. Appl. No. 11/610,671 Office Action dated Oct. 20, 2011. |
U.S. Appl. No. 11/610,671 Office Action dated Oct. 8, 2014. |
U.S. Appl. No. 11/610,671 Office Action dated Sep. 12, 2013. |
U.S. Appl. No. 12/406,316 Office Action dated Apr. 4, 2012. |
U.S. Appl. No. 12/406,316 Office Action dated Apr. 5, 2013. |
U.S. Appl. No. 12/406,316 Office Action dated Aug. 10, 2011. |
U.S. Appl. No. 12/406,316 Office Action dated Nov. 26, 2012. |
U.S. Appl. No. 14/114,517 Office Action dated Aug. 13, 2015. |
U.S. Appl. No. 13/990,755 Office Action dated Jan. 19, 2017. |
U.S. Appl. No. 09/997,545 Office Action dated Feb. 10, 2003. |
U.S. Appl. No. 09/997,545 Office Action dated Jul. 3, 2002. |
U.S. Appl. No. 10/734,784 Office Action dated Apr. 4, 2007. |
U.S. Appl. No. 13/124,472 Office Action dated Feb. 16, 2016. |
U.S. Appl. No. 13/124,472 Office Action dated Jan. 18, 2013. |
U.S. Appl. No. 13/124,472 Office Action dated Jun. 21, 2013. |
U.S. Appl. No. 13/124,472 Office Action dated Jun. 4, 2015. |
U.S. Appl. No. 13/124,472 Office Action dated Oct. 3, 2014. |
U.S. Appl. No. 13/990,755 Advisory Action dated Jan. 2, 2019. |
U.S. Appl. No. 13/990,755 Office Action dated Jun. 29, 2017. |
U.S. Appl. No. 13/990,755 Office Action dated May 5, 2016. |
U.S. Appl. No. 14/114,517 Office Action dated Apr. 23, 2015. |
U.S. Appl. No. 14/114,517 Office Action dated Mar. 24, 2016. |
U.S. Appl. No. 14/114,517 Office Action dated Oct. 20, 2016. |
U.S. Appl. No. 14/654,498 Office Action dated Jul. 27, 2017. |
U.S. Appl. No. 14/654,498 Office Action dated May 3, 2018. |
U.S. Appl. No. 14/654,498 Office Action dated Nov. 17, 2017. |
U.S. Appl. No. 14/795,176 Office Action dated Feb. 3, 2016. |
U.S. Appl. No. 14/889,818 Office Action dated Feb. 26, 2019. |
U.S. Appl. No. 14/889,818 Office Action dated Jan. 10, 2018. |
U.S. Appl. No. 14/889,818 Office Action dated Jan. 25, 2017. |
U.S. Appl. No. 14/889,818 Office Action dated Jun. 19, 2018. |
U.S. Appl. No. 14/889,818 Office Action dated Jun. 9, 2017. |
U.S. Appl. No. 14,889,818 Office Action dated Sep. 27, 2016. |
U.S. Appl. No. 15/372,299 Final Office Action dated Nov. 9, 2018. |
U.S. Appl. No. 13/990,755 Office Action dated Apr. 5, 2018. |
U.S. Appl. No. 15/372,299 Office Action dated Apr. 23, 2018. |
Usacheva et al., Interaction of the photobactericides methylene blue and toluidine blue with a fluorophore in Pseudomonas aeruginosa cells. Lasers in Surgery and Medicine, 40:55-61, 2008. |
Varani et al., Human skin in organ culture and human skin cells (keratinocytes and fibroblasts) in monolayer culture for assessment of chemically induced skin damage. Toxicol Pathol., 35(5):693-701, 2007. |
Vengerovsky, A.I., Pharmaceutical incompatibility. Bulletin of Siberian Medicine, 3:12 pages, 2003. http.7/old.ssmu.ru/bull/03/3/1684.pdf. |
Wainwright. Photodynamic antimicrobial chemotherapy (PACT). Journal of Antimicrobial Chemotherapy, 42:13-28, 1998. |
Wainwright et al., The Use of new methylene blue in Pseudomonas aeruginosa biofilm destruction. Biofouling, 18:247-249, 2002. (Abstract only). |
Walker M, Bowler P, Cochrane C. In vitro studies to show sequestration of matrix metalloproteinases by silver-containing wound care products. Ostomy Wound Manage. 2007; 53: 18-25. |
Walker M, Metcalf D, Parsons D, Bowler P. A real-life clinical evaluation of a next-generation antimicrobial dressing on acute and chronic wounds. J Wound Care. 2015; 24: 11-22. |
Waring et al. Physico-chemical characterisation of carboxymethylated spun cellulose fibres. Biomaterials 22:903-912 (2001). |
Webb R. A chronic case of confusion. J of Wound Care. 2017; 26: 421. |
Welsby S. The Spectrum Activity of AQUACEL Ag+ with Strengthening Fibre Ribbon using an In Vitro Corrected Zone of Inhibition Assay. 2015. ConvaTec data on file. |
White, “An historical overview of the use of silver in wound management,” Actisorb Silver 220, The Silver Supplement Part Two: Clinical Evidence, 6(Supp. Pt. 2): 6 pages (2001). |
Wilkinson H, Stephenson C, Hardman M. Comparing the effectiveness of polymer debriding devices using a porcine wound biofilm model. Adv Wound Care. 2016; 5: 475-85. |
Wirtanen, et al., Performance Evaluation of disinfectant Formulations Using Poloxamer-hydrogel Biofilm-constructs, Journal of Applied Microbiology, 85:965-971, 1998. |
Wolcott R. Biofilms cause chronic infections. J of Wound Care. 2017; 26: 423-5. |
Wolcott R. Disrupting the biofilm matrix improves wound healing outcomes. J Wound Care. 2015; 24: 366-71. |
Wolcott R, Rhoads D. A study of biofilm-based wound management in subjects with critical limb ischemia. J Wound Care. 2008; 17: 145-55. |
Wolcott R, Sanford N, Gabrilska R, Oates J, Wilkinson, J, Rumbaugh K. Microbiota is a primary cause of pathogenesis of chronic wounds. J Wound Care. 2016; 25: Sup10: S33-S43. |
Wood et al., Erythrosine is a potential photosensitizer for the photodynamic therapy of oral plaque biofilms. Journal of Antimicrobial Chemotherapy, 57:680-684, 2006. |
Zölß C, Cech JD. Efficacy of a new multifunctional surfactant-based biomaterial dressing with 1% silver sulphadiazine in chronic wounds. Int Wound J. 2016; 13: 738-43. doi: 10.1111/iwj.12361. |
Canadian Office Action, Canadian Intellectual Property Office, Canadian Patent Application No. 2,819,303, dated Oct. 30, 2018, 4 pages. |
Japanese Search Report, Japan Patent Office, Japanese Patent Application No. 2018-128781, dated May 28, 2019, 12 pages. |
Japanese Office Action, Japan Patent Office, Japanese Patent Application No. 2018-128781, dated Nov. 26, 2019, 3 pages. |
Canadian Office Action, Canadian Intellectual Property Office, Canadian Patent Application No. 2,819,303, dated Nov. 28, 2019, 3 pages. |
Japanese Pre-Appeal Examination Report, Japan Patent Office, Japanese Patent Application No. 2018-1128781, dated Aug. 6, 2020, 2 pages. |
Notification of Reasons for Refusal, Japan Patent Office, Japanese Patent Application No. 2018-128781, dated Dec. 1, 2020, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20190216953 A1 | Jul 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13990755 | US | |
Child | 16295774 | US |